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Abstract 
Systemic Lupus Erythematosus (SLE) is an autoimmune disease which is well 
characterized by the over production of proinflammatory cytokines such as type I 
interferons (IFN) and TNFα, downstream of the pathogen recognition toll-like receptors, 
TLR-7 and TLR-9.  Sialic Acid Immunoglobulin-Like Lectins (Siglecs) are cell surface 
receptors that have previously shown to be negative regulators of type I IFNs.  Murine 
Siglec-E is one such negative regulator that has the ability to inhibit TLR driven IFN 
production.  PLGA nanoparticles conjugated to the sialic acid ligand of Siglec-E (Sia NPs) 
were observed to inhibit production of the pro-inflammatory cytokine, TNFα in murine 
peritoneal macrophages.  Biodistribution analysis in mice showed that fluorescently 
labeled- Sia NPs localized to areas known to have high levels of Siglec-E expression.  The 
aim of this study was to evaluate the capability of these nanoparticles to activate the 
human orthologues of Siglec-E, Siglec-7 and Siglec-9, in human peripheral blood 
mononuclear cells in order to investigate their potential as a therapeutic modality in SLE 
patients.  Expression analysis demonstrated that SLE patients display lower levels of 
Siglec-7 and Siglec-9 expression in resting immune cells compared to healthy controls. 
Following stimulation, Siglec-7 is upregulated in peripheral blood mononuclear cells.  
Unexpectedly however, addition of Sia NPs resulted in exacerbation of the 
proinflammatory response as measured by TNF-α and RANTES expression suggesting that 
Siglec-7, while it possesses an inhibitory motif, may in fact be acting in a pro-
inflammatory manner.  Screening of other potential ligands identified sialic acid GD3 as 
an inhibitor of TLR and immune complex driven cytokine production in immune cells. 
Whether this is mediated by Siglec 7 however was not determined. Further investigation 
into the role of Siglec-7 in SLE patient monocytes and immune cells is required before it 
can be determined to be a good target for activation with sialic acid coated nanoparticles.  
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1.1 Autoimmunity 
 
In healthy individuals, an immune response is initiated after recognition of a foreign 
antigen by the cells of the immune system such as natural killer cells, macrophages,  
T cells and B cells to name a few.  The cells of the innate immune system can phagocytose 
and clear the pathogen.  In addition they act to present antigen to the cells of the 
adaptive arm and secrete cytokines that activate T and B cells and in doing so tailor the 
immune response according to the pathogen or threat perceived.  Alternatively, antigen 
presenting cells can stimulate antibody and cytokine production which also ultimately 
leads to the clearance of the pathogen. However, autoimmunity occurs when there is a 
breakdown in self-tolerance and T and B cells recognise and respond to self-antigens.  
Autoantibodies are present in individuals with and without an autoimmune disease and 
while most individuals are capable of suppressing an autoimmune response even in the 
presence of these autoantibodies, those who cannot will present with an autoimmune 
disease. Autoimmune diseases can be systemic (Rheumatoid Arthritis, Sjögren’s 
Syndrome, Systemic Lupus Erythematosus) or organ specific (Coeliac Disease, Multiple 
Sclerosis, Grave’s Disease).  
 Defective phagocytosis is a feature of many systemic autoimmune diseases, 
including systemic lupus erythematosus (SLE) and can lead to a build-up of self RNA and 
DNA which is released from dead and dying cells and subsequently not cleared as normal 
by macrophages. In systemic disease, autoantibodies recognise self-RNA and self-DNA as 
self-antigens and form complexes with them; these are known as immune complexes 
(ICs).  As shown in Figure 1-1 these ICs then bind to the Fc receptor, present on cell 
surfaces.  Not only do Fc receptors themselves help activate cells but they can also deliver 
the self-RNA/DNA to a family of innate immune receptors called Toll-like receptors (TLRs) 
on or in the cell, thereby stimulating them, and promoting the activation of inflammatory 
cascades resulting in the overproduction of cytokines that are characteristically observed 
in an autoimmune response. 
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Figure 1-1:  The role of immune-complexes in autoimmunity. In individuals with an autoimmune 
disease, autoantibodies bind to self-antigens (e.g. dsDNA) forming an immune complex. These 
immune complexes then bind to Fc Receptors present on the cell surface. The Fc Receptor can then 
deliver the dsDNA to endosomal receptors such as TLRs 3, 7 & 9. 
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1.2 Systemic Lupus Erythematosus (SLE) 
 
Systemic Lupus Erythematosus is a systemic autoimmune disease characterised by 
the production of anti-nuclear antibodies (ANAs) as described above.  Typical 
manifestations include, but are not limited to, a distinctive butterfly shaped rash across 
the nose and cheeks, photosensitivity, oral ulcers and arthritis.  The immune complexes 
described above are also prevalent in SLE and can cause nephritis in the kidneys [1].  The 
SLE Disease Activity Index (SLEDAI) [2] is then used to determine the level of SLE activity in 
patients. 
  
Innate immune system in SLE: The initial cause of SLE is unknown; however it is seen in 
females at a ratio of 9:1 compared to males, suggesting that hormones such as estrogen 
could be involved in the onset of the disease [3, 4].  A combination of TLRs, immune 
complexes (ICs), the pro-inflammatory cytokines (such as IL-1 and IL-6), and antiviral 
cytokines–the type I interferons (IFNS), have been shown to be heavily involved in the 
disease pathogenesis [5-7].  An over-production of type I IFNs in SLE patients contributes 
to unnecessary inflammation and tissue damage.  The cause of this over-production is 
thought to be stimulation of the viral TLRs 3, 7 & 9. Smith et al showed that over 
production of the proinflammatory cytokine, IL-23, in SLE patients as a result of IRF3 
binding to the IL-23p19 is caused by enhanced TLR3 activation [8], whereas TLRs 7 & 9 are 
stimulated by ICs via the Fc Receptor FcγRIIa (Figure 1-2)[9].   The ICs can bind to FcγRIIa, 
the Fc receptor then delivers the DNA from the IC to the endosome where TLRs 7 & 9 
reside, thus leading to their stimulation.  This stimulation leads to activation of pathways 
resulting in the activation of transcription factors NFκB and interferon regulatory factors 
(IRFs) 3 and 7 which together drive type I IFN production. At a genetic level, enhanced 
levels of both TLR 7 and 9 have shown to play a role in the pathogenesis of SLE [10, 11]. 
  
Negative regulators of IFN pathways as potential novel therapeutic targets: There is 
currently no cure for SLE and patients are treated depending on their symptoms.  The 
most common treatments are nonsteroidal anti-inflammatory drugs (NSAIDs), 
antimalarial drugs, corticosteroids and immune suppressants.  The latest emerging 
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treatment is belimumab which targets B-lymphocyte stimulator (BLys) to counteract 
autoantibody production.  Belimumab-treated patients display significantly reduced 
SLEDAI score, however African-American patients showed no improvement [12].  
 Our lab investigates potential negative regulators of the disease and the possibility 
of developing these into therapeutics.  One regulator that has already been identified is 
the E3 ubiquitin ligase, TRIM21.  TRIM21 targets the transcription factors IRF3 and IRF7 
for ubiquitination and subsequent degradation.  Down regulation of the transcription 
factor IRF3 can lead to decreased IFN-β production thus making it a negative regulator of 
IFN production and an important protector against the development of 
autoimmunity[13], [14].  
 The inositol phosphatase, SHIP-1, has also been shown to negatively regulate  
TLR-3 induced IFN production by targeting the downstream kinase, TBK-1, [15] and 
subsequently blocking the phosphorylation of IRF3 and IRF7 which would have led to 
induction of type I IFN production.  Small molecule agonists of SHIP-1 have proven to be 
effective in inhibition of mast cell and macrophage activation and have reduced 
inflammation in a murine model of inflammation by inhibiting the PI3K pathway, which 
has a prominent role in cellular activation [16]  AQX-1125 is a small molecule agonist of 
SHIP-1 which is currently in phase II clinical trials for the treatment of chronic obstructive 
pulmonary disease and interstitial cystitis – both inflammatory diseases affecting mucosal 
sites [17]. 
 Many other inhibitory pathways exist that can dampen down the immune 
response and play a role in protecting against autoimmune disease.  For example, the 
receptor TIR8/SIGIRR can inhibit IL-1 and TLR-4 mediated inflammation by interfering with 
the formation of the receptor complex and subsequently blocking the recruitment of the 
adapter molecule MyD88, which is essential in eliciting a proinflammatory response [18].  
In addition to this SIGIRR knockout MLR/Lpr mice displayed increased production of 
autoantibodies and enhanced disease pathology [19] and in SIGIRR knockout mice, 
injection of pristane intraperitoneally to mimic IFN driven SLE, the mice showed increased 
susceptibility to lupus nephritis [20]. 
As previously discussed, defective clearing of RNA and DNA from dead and dying 
cells can lead to the formation of immune complexes. The family of tyrosine kinase 
receptors known as TAM (Tyro-3, Axl and Mer) are essential in this phagocytic process 
17 
 
[21] and thus are considered negative regulators of TLR induced inflammation. Li et al 
demonstrated the potential role for these receptors in inflammatory disease this by 
developing TAM knockout mice that displayed elevated levels of proinflammatory 
cytokines and type I IFNs [22]. 
FcγRIIb is an additional inhibitory receptor that is found on the surface of B cells 
and polymorphisms in this protein that lead to loss of or reduced function are associated 
with the development of SLE.  FcγRIIb contains a cytoplasmic tail consisting of an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) that is responsible for recruiting 
in inhibitory signalling proteins such as phosphatases SHP1/2 and thus transmitting 
inhibitory signals to cells.  Also present on the B-cell surface is the B-cell receptor (BCR) 
which conversely has an immunoreceptor tyrosine-based activator motif (ITAM) in its 
cytoplasmic tail.  In SLE patients, the delicate balance in the pro- and anti-inflammatory 
response of these receptors on B-cells has been lost.  Thus restoring this balance by 
triggering activation of inhibitory receptors such as FcγRIIb is a potential strategy in the 
treatment of SLE. Such strategies have been examined in other autoimmune disorders.  
For example, T-cell Ig and mucin domain protein 3 (Tim-3) has emerged as a negative 
regulator with therapeutic potential.  Reduced Tim-3 expression has been shown to 
enhance T-cell function in autoimmune diseases such as autoimmune hepatitis [23].  
Koguchi et al demonstrated that decreased Tim-3 expression in an MS model lead to 
increased IFN-γ levels and cell proliferation [24].  
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Figure 1-2 The role of immune-complexes in SLE.  In SLE, immune complexes signal through the Fc 
Receptor, as described in Figure 1.1. The antiviral TLRs 7 & 9 are found in the endosome. dsDNA from 
immune complexes binds to TLR7 thus activating the downstream pathway via the adaptor molecule 
MyD88. This pathway leads to the over-production of type I IFNs which are a major contributor to 
the disease pathogenesis of SLE.  
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1.3 Siglecs 
 
Sialic acid binding Ig-like lectins (Siglecs) are transmembrane receptors found on the 
cells of the immune system.  To date, 14 human Siglecs have been identified.  They are 
broken into two subsets:  Siglecs 1 (Sialoadhesin), 2 (CD-22), 4 (Myelin-associated 
glycoprotein or MAG) and 15 are considered to be the evolutionarily conserved Siglecs; 
and the CD33-related Siglecs ; Siglec 3 (CD-33) and Siglecs 5 – 11, 14 & 16, some of which 
are inhibitory in the immune system.  In the context of SLE, the CD33 related receptors 
are of interest due to their potential inhibitory roles in the immune system. 
The basic structure of all of the CD33-related Siglecs is made up of a sialic acid 
binding domain and a variable number of C2-set domains extracellularly, then 
intracellularly there are tyrosine-based signalling motifs (Figure 1-3).  These signalling 
domains in the cytoplasmic tail are called immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs).  Upon activation of the Siglec, the ITIM becomes phosphorylated and can 
recruit and activate the tyrosine phosphatases SHP-1 and SHP-2 [25], thus giving itself the 
potential to inhibit tyrosine kinase-driven pathways, such as those involved in SLE 
pathogenesis. 
Cells can express more than one Siglec at a time, e.g. monocytes can express 
Siglec-3, -5 -7 -10 and -11, indicating that each receptor has its own specific ligand and 
function.  Not all of the specific sialic acids associated with each Siglec are known, 
however, it is known that Siglecs can bind their cognate ligands in cis (i.e. binding of 
receptor and ligand on the same cell) and trans (binding of a Siglec on one cell with a 
sialic acid on another cell).  When bound in cis with sialic acids expressed on the same 
cell, the Siglecs are thought to be masked and not activated but when they bind to sialic 
acids on other cells or on pathogens they are unmasked and are ‘active’ – i.e. can exert 
their inhibitory or activatory effects depending on their function. Therefore the 
suggestion is that depending on what type of interaction the Siglec is involved in, it may 
function differently [26]. 
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Figure 1-3 A schematic of the CD33-related Siglecs 7/9. Siglecs-7 & -9 are structurally similar 
transmembrane receptor proteins. They are made up of the sialic-acid binding V-set domain, a 
variable length C-2 set domain and a cytoplasmic tail containing an inhibitory motif known as an tails 
are called immunoreceptor tyrosine-based inhibitory motif (ITIM). 
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1.4 CD33 Related Siglecs in the Immune System 
 
As mentioned above, Siglecs are present on cells of the immune system and can 
inhibit tyrosine kinase signalling.  Of particular interest to us was the relationship 
between TLR signalling and Siglecs.  Stimulation of TLR 4 with Lipopolysaccharide (LPS) 
causes an increase in the expression and release of pro-inflammatory cytokines [27].  In 
2010 Ohta et al showed that cells over-expressing Siglec-9 could dampen the 
inflammatory response caused by stimulation of TLR-4 with LPS, a result not seen when 
the ITIM was mutated, suggesting that Siglec-9 is capable of inhibiting TLR-4 activity [28]. 
Siglec-7 has been shown to be capable of inhibitory functions on natural killer (NK) cells.  
Cancerous cells expressing ganglioside GD3, a known ligand of Siglec-7, can utilize its 
ability to inhibit NK cell toxicity to evade the immune response [29]. Orr et al then 
exploited this knowledge and demonstrated the therapeutic potential of Siglec-7 in 
relation to myeloid leukaemia by targeting it for proteasomal degradation with SOCS3 
thus rescinding its ability to inhibit cytokine-induced cell proliferation [30].   
In contrast, a number of CD33-related Siglecs are thought to have activating 
properties within the immune system.  These are Siglecs-14 and -16 in humans, Siglec-15 
in humans and rodents and Siglec-H in rodents only.  They do not have an inhibitory motif 
in their cytoplasmic tails but instead have a region that is capable of binding to the 
adaptor molecule DAP12 which contributes to cellular activation [31]. 
 The balance between the inhibitory and activating properties of Siglecs is very 
delicate and driving it too far in either direction could be detrimental.  
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1.5 Significance of Siglec E 
 
For the purposes of this project we were only interested in the inhibitory properties 
of Siglecs and the potential to manipulate these properties and develop prospective 
therapeutic for the treatment of SLE.  A collaboration with Prof. Jim Johnson’s lab in 
Queen’s University Belfast resulted in the identification of a rodent specific Siglec,  
Siglec-E, that was up-regulated in a MyD88 specific manner following TLR4 stimulation 
with LPS.  It was also shown to recruit SHP-1 and SHP-2 and inhibit IFN-β production, thus 
indicating it as an inhibitory receptor [32].  
 Clustal W analyses and T-coffee alignments of Siglec-7 & -9 and Siglec-E show high 
levels of homology and functional similarity between the human and murine genes 
(Figure 1-4).  Thus Siglec-E was a natural target for the development of anti-inflammatory 
strategies, whose human orthologues Siglec-7 and Siglec-9 are expressed on monocytes 
and which might be manipulated in order to inhibit or dampen the immune response in 
SLE patients.  
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Figure 1-4 A T-Coffee alignment of murine Siglec-E and human Siglec-7.  This figure shows the 53% 
homology seen between murine Siglec-E and human Siglec-7 as determined by the multiple sequence 
alignment software T-Coffee.  
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1.6 Sialic Acids – Ligands for Siglecs 
 
Sialic acids are nine carbon monosaccharides found on the cell surface in 
vertebrates and also in bacteria and viruses.  Their structural diversity is immense and so 
for this project, only their role in relation to Siglec binding will be discussed. 
 Sialic acids are linked to underlying sugars by the carrier enzymes called 
sialyltransferases.  The most common linkages in animals are via their carbon 2 site to the 
carbon 3 or carbon 6 sites of galactose residues [33] (Figure 1-6).  When bound to the 
carbon 3 site this is commonly called an α 2,3 linkage or when bound to the carbon 6 site 
it is known as an α 2,6 linkage.  Depending on the linkages and resulting structure, there 
will be a higher or lower affinity for binding to specific sialic acids by individual Siglecs. 
Individual expression patterns and specificities of particular Siglecs for specific Sialic Acid 
linkages are given in Table 1-1, adapted from Cao et al [31].  
 Siglecs are common cell surface receptors with a high affinity for sialic acids. As 
sialic acid is found in abundance on cell surfaces, therefore the cis binding formation 
discussed earlier, whereby the receptor binds to sialic acids on the same cell surface, is 
relatively common and means that these receptors are blocked and cannot link to any 
other sialic acids.  However, some receptors, such as Siglec-2 (or CD22) found on B-cells, 
have a higher affinity for trans interactions. This was shown by Lanoue et al when they 
demonstrated that Siglec-2 mediated B-cell activation in response to antigen-presenting 
cells was lowered if the antigen was expressed on the same cell as the Siglec-2 [34]. 
 Thus the affinity for specific sialic acids and the potential that various cell types 
might express both ligand and receptor means that targeting Siglecs for therapeutic 
manipulation is a complicated process which may lead to under activation of the receptor 
if the concentration of the ligand is too low or activation of the receptor if the 
concentration is high enough to promote trans association or activation of the receptor. 
These complicating factors must be considered when developing particle-based 
therapeutics conjugated to sialic acids.  
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Figure 1-5.  Sigles in cis and trans interactions.  A shows a masked Siglec in a cis interaction with a 
sialylated cell-surface glycan.  Sialidases or sialic acids with a higher affinity for these Siglecs can 
disrupt this interaction.  B shows a Siglec in a trans interaction with a pathogen that displays a sialic 
acid on its surface. This is a common method of infection used by pathogens.  Trans interactions can 
also be cell-cell binding via sialic acid sand Siglecs. 
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Table 1-1:  A list of preferred glycan ligands for human Siglecs 
Human Siglec Cellular Expression Preferred Glycan 
Siglec-3 
Myeloid progenitors, 
monocytes 
α 2,6 
Siglec-5 Neutrophils, B cells α 2,6 & α 2,3 
Siglec-6 Trophoblasts, B-cells Sialyl Tn structures 
Siglec-7 
Natural killer cells, 
subset of CD8 T cells, 
monocytes 
α 2,8, weaker to α 2,6 & 
α 2,3 
Siglec-8 Eosinophils, basophils 
6’-sulphated Sialyl Lewis 
X 
Siglce-9 
Neutrophils, monocytes, 
dendritic cells. 
α 2,6 and α 2,3 
Siglec-10 
Natural killer-like cells, B 
cells, monocytes, 
Eosinophils 
α 2,6, α 2,3, vascular 
adhesion molecule-1, 
CD24 glycoforms 
Siglec-14 Neutrophils, monocytes α 2,6 & α 2,3 
*Siglec-11 
Macrophages α 2,8 
*Siglec-16 
 
*Siglec11 locus comprises both Siglec 11 and Siglec 16. There are two alleles of 
Siglec-16. One is functional and one is a pseudogene containing a 4 bp deletion. 
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Adapted from http://effectmeasure.blogspot.ie/2006/01/background-science-for-turkish_18.html 
 
 
 
 
 
 
 
Figure 1-6 Different alpha linkages seen in sialic acids and the chemical structure of Ganglioside 
GD3.  A shows a sialic acid linked to a glycan by an α 2,6 linkage, while B shows an α 2,8 linkage.  C is 
the chemical structure of the sialic acid GD3, which we found to inhibit the Type I IFN response in 
stimulated monocytes. 
Ganglioside GD3 
Adapted from http://www.mskcc.org/research/lab/alan-houghton/lab/development-new-therapies 
C 
A B 
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1.7 Nanoparticles 
 
Polymeric nanoparticles (NPs) have been identified as a potential method for 
targeted drug delivery.  These biodegradable particles often comprise drugs, proteins or 
shRNA encapsulated in a polylactic co-glycolic acid (PLGA) and polyethylene glycol (PEG) 
shell [35].  This method of drug delivery has emerged as a potential therapeutics for 
prostate cancer [36], liver cancer [37] and colon cancer [38] to name a few. Regarding 
inflammation, nanoparticles are an efficient method of delivering drugs to sites of 
inflammation that are difficult to reach.  For example with Inflammatory Bowel Disease 
(IBD), inflammation occurs in the colon which can prove difficult to target specifically. 
However, nanoparticles encapsulating an anti-inflammatory drug have proven to protect 
against a dextran sodium sulphate induced inflammatory response in a murine model of 
colitis [39]. In addition to drugs, nanoparticles have proven to be successful in delivering 
small interfering RNAs (siRNAs) to target the overexpression of CD98 on the surface of 
colonic epithelial cells in the treatment of IBD [40].One study shows the ability of 
nanoparticles loaded with Curcumin, to suppress the phosphorylation of p38MAPK in 
TNFα activated human endothelial cells, thus reducing the inflammatory response [41].  
 PLGA NPs conjugated to an α 2,8 linked sialic acid were developed in Dr. Chris 
Scott’s lab in Queen’s University Belfast.  These were observed to reduce the 
inflammatory response in murine cells but not in human cells when tested (unpublished 
data).  The NPs are an ideal method for delivering sialic acids specific to inhibitory Siglecs 
in our system, as they are reportedly non-immunogenic and stable  In addition to this it 
has been shown that monocytes do not differentiate following binding to nude 
nanoparticles [42] and therefore the NPs should not induce an undesirable inflammatory 
response.  
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1.8 Aims and Hypothesis 
 
 Given the inhibitory effects of the Sia NPs observed in murine cells we 
hypothesised that the Sia NPs would successfully inhibit the inflammatory response in 
human cells as they did in murine peritoneal macrophages.  We then hoped to test them 
in cells derived from SLE patient samples.  Once we determined their ability to work in a 
human SLE model we would assess the biodistribution of the Sia NPs in healthy mice and 
then develop a murine model of SLE IFN-driven disease an in vivo model.  The 
nanoparticles would then be injected into the SLE mice to measure their potential to 
inhibit TNFα and IFN production.   
Initially our aims were  
1) To investigate the distribution, stability and toxicity of these molecules in vivo. 
2) To assess the activity of the sialic acid conjugated nanoparticles (Sia NPs) in 
healthy human cells and eventually SLE patient cells. 
3) To evaluate the in vivo efficacy of the Sia NPs in a murine model of SLE. 
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2. Materials and Methods 
 
31 
 
2.1 Materials 
 
This section includes a list of products and instruments used in this study, including the 
manufacturer they came from.  The full names and addresses of manufacturers are 
included at the end of this section.  All solutions were prepared using pure deionised 
water.  Room temperature (RT) was 20 ± 5C. 
 
Table 2-1.  Materials Used 
Product/Instrument Manufacturer 
autoMACS Running Buffer Miltenyi Biotec 
Bovine Serum Albumin (BSA)  Sigma 
Buffer Exchange Centrifugal Filters Amicon 
Chloroform Sigma 
Dichloromethane (DCM) Sigma 
Ficoll-Paque PLUS GE Healthcare 
Foetal Calf Serum (FCS) Biosera 
Gentamicin Sigma 
Go Taq 5X Colourless Buffer Promega 
Go Taq Polymerase Promega 
HiTrap Protein G columns GE Healthcare 
huCpG(A) oligodeoxynucleotides (ODN) 
2216 
Invivogen 
IL-6 ELISA Duoset R & D Systems 
Imiquimod Invivogen 
Immobilon Western Chemiluminescent 
Horse Radish Perosidase (HRP) Substrate 
Millipore 
Isopropyl alcohol Sigma 
Lipopolysaccharide (LPS) Invivogen 
LS Columns Miltenyi Biotec 
MACS Separator Miltenyi Biotec 
Monocyte Isolation Kit II Miltenyi Biotec 
Nanodrop1000 Mason Technology 
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Product/Instrument Manufacturer 
Nunc Maxisorp 96-well plates eBiosciences 
Passive lysis buffer Promega 
Penicillin/Streptomycin Solution 100x Biosera 
Phosphate Buffered Saline (PBS) Biosera 
Poly (lactic-co-glycolic acid) (PLGA) 503 Boehringer Ingelheim 
Polyvinyl Alcohol (PVA) Sigma 
Probe sonicator Branson 
Quantitech Reverse Transcriptase Kit Qiagen 
RANTES/CCL5 Duoset ELISA kit R & D 
Red Cell Lysis Buffer Sigma 
RPMI 1640 Biosera 
Sodium Citrate Sigma 
Sulfuric Acid Sigma 
Tris Sigma 
TRIZOL™ Sigma 
Trypan Blue Biosera 
Trypsin-EDTA Biosera 
Tumor Necrosis Factor α (TNFα) ELISA 
Duoset 
R & D Systems 
Tween 20 Sigma 
Victor Wallac Multiplate Reader PerkinElmer 
Zetasizer Malvern 
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2.2 Methods 
 
2.2.1 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from Whole Blood 
 
Blood was drawn from a healthy donor into a syringe containing 10% sodium citrate 
to prevent coagulation.  The blood was then left on a rocker for 30 min to mix.  The blood 
was separated into 15 ml aliquots and diluted 1:1 with PBS.  This mixture was layered 
onto a Ficoll gradient and spun with no brake at 300 rcfs for 30 min.  The buffy coat of the 
resulting gradient was removed using a Pasteur pipette and transferred to a fresh tube.  
These cells were spun at 400 rcfs with a brake for 5 mins.  If red blood cells were present, 
the cells were resuspended in 2 ml of PBS then 3 ml of red blood cell lysis buffer was 
added and mixed well.  This was then diluted to 50 ml with PBS and centrifuged at 
400 rcfs for 5 mins.  The lysis step was repeated if required.  The final pellet was 
resuspended in 10 ml RPMI 10% (v/v) fetal calf serum (FCS) and 100 mg/ml Gentamicin 
and counted. 
 
2.2.2 Negative Selection of Monocytes from Primary Human PBMCs 
 
Monocytes were isolated from PBMCs using Monocyte Isolation Kit II from Miltenyi 
Biotec.  Once counted, PBMCs were centrifuged at 3000 g for 10 min.  The resulting pellet 
was resuspended in 30 µl of autoMACS running buffer per 107 cells.  10 µl of FcR Blocking 
agent and 10 µl of antibody cocktail were added per 107 cells.  This was mixed well and 
incubated for 15 mins at 4-8 °C.  30 µl of buffer and 20 µl of Anti-Biotin Microbeads were 
then added per 107 cells.  This was mixed and incubated for 20 mins at 4-8 °C.  The cells 
were then washed with 2mL of buffer and centrifuged at 3000 g for 10 min.  All of the 
supernatant was removed using a pipette.  The cells were resuspended in 500 µl buffer 
per 108 cells.  
An LS column was placed in the MACS Separator and rinsed with 3 mL of buffer.  
The flow-through was collected in a waste container.  The cell suspension was then added 
to the column and the flow-through (containing the monocytes) was collected in a fresh 
tube.  The column was then washed with 3 x 3 mL of buffer and the effluent was collected 
in the same tube as the flow through from the cell suspension.  This was spun at 5000 g 
for 5 min and the pellet was resuspended in RPMI medium. 
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2.2.3 Isolation of IgG from Active Patient Serum 
 
Frozen serum from patients with active disease was defrosted on ice.  All reagents 
and serum was filtered through a 0.45 µm filter.  HiTrap Protein G columns were 
prepared by attaching the luer adaptor (syringe adaptor) supplied to the top of the 
column and removing the snap-off end.  A syringe containing binding buffer was attached 
“drop to drop” to the column via the luer adaptor to prevent the introduction of air 
bubbles.  10 column volumes (10 ml) of binding buffer were passed through the column 
at a rate of 1 ml/min and the flow-through was collected in a waste container.  The 
filtered serum was then added in the same manner at a rate of 1 ml/min and the flow 
through was collected in a waste container.  The column is then washed with 5-10 column 
volumes of binding buffer to remove any residual, unbound protein.  These washes are 
collected in 1 ml fractions and the A280 of each fraction was determined until there was 
no protein present.  
 Collection tubes were then prepared by adding 10% final volume of Tris-HCl to 
each tube.  The column was then flushed with 5–10 column volumes of elution buffer and 
this was collected in 1 ml fractions in the pre-prepared tubes containing neutralization 
buffer.  The A280 of the eluates was measured until there was no protein present.  The 
eluates with the highest protein concentrations were then combined.  
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2.2.4 Buffer Exchange and Concentration of IgG Isolated from Serum 
 
The isolated IgG sample was then added in 500 ml fractions to the Amicon 0.5 ml 
Centrifugal Filters.  These were spun at 14,000 g for 10 mins at room temperature and 
after this time approximately 20 µl remains in the filter.  480 µl of sterile PBS was then 
added back onto the filter and this was spun at 14,000 g for 10 min at room temperature.  
The filter was then turned up-side-down in the collection tube provided and spun at 
1,000 g for 2 min at room temperature.  Approximately 20 µl is left from each sample and 
IgG is now in PBS.  All 20 µl fractions were combined and concentration was determined 
by measuring the A280.  The final sample was aliquoted and stored at -80 °C. 
 
2.2.5 Enzyme-Linked Immunosorbent Assay 
 
ELISAs were carried out using DuoSet® ELISA Development Kits for TNFα, IL-6 and 
RANTES (R and D Systems).  A 96 well microtitre plate was coated with 50 µl/well of the 
capture reagent (diluted in PBS) overnight at 4 °C.  The plate was washed 3 times with 
wash buffer (PBS-0.1 (v/v) Tween-20) and blocked for 1 hr at RT in blocking buffer (5% 
(w/v) BSA in PBS).  The plate was washed 3 times with wash buffer and 50 µl of samples 
or standards ranging from 0 pg/ml to 2000 pg/ml were added to the plate in triplicate and 
incubated for 2 hr at RT.  Again the plate was washed 3 times with wash buffer and 
50 µl/well of biotinylated detection reagent (diluted in 1% (w/v) BSA in PBS) was added 
to each well and incubated for 2 hr at RT.  The plate was washed 3 times with wash buffer 
and 50 µl/well then Streptavidin-HRP (diluted 1 in 200 in 1% (w/v) BSA in PBS) was added 
to each well for 20 min at RT.  The plate was again washed 3 times with wash buffer and 
50 µl/well of 3,3',5,5'-Tetramethylbenzidine (TMB) was added for a further 20 min at RT.  
50 µl/well sulphuric acid was added to stop the reaction.  The optical density of the 
standards and samples was read at 450 nm on the Victor Wallac Multiplate Reader and a 
standard curve was constructed from which the concentrations in the samples could be 
extrapolated. 
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2.2.6 mRNA extraction and cDNA synthesis: 
 
Cells were homogenised in 1 ml of Tri-reagent (Sigma) for 5 min at 15-30 °C.  
0.2 ml of chloroform was added to samples and microfuge tubes were shaken vigorously 
by hand for 15 sec and then incubated at RT for 2-3 min.  Samples were spun at 12,000 g 
for 15 min at 4 °C which caused samples to separate into lower red phenol-chloroform 
phase containing cellular proteins, an interphase containing the DNA and a colourless 
upper aqueous phase containing the RNA.  The upper aqueous phase was transferred to a 
clean microfuge tube and 0.5 ml of isopropyl alcohol was added to this.  Samples were 
incubated for 10 min at RT and spun at 12000 g for 10 min at 4 °C.  Supernatant was 
removed and the RNA pellet was washed with 1 ml of 70 ethanol.  Sample was mixed 
well by vortexing and spun at 7500 g for 5 min at 4 °C.  Supernatant was removed and 
RNA pellet was allowed to air dry.  RNA was then dissolved in 50 µl of RNase-free water 
and concentration was determined on the nanodrop (Mason Technology) before storage 
at -80 °C until needed. 
 cDNA was made using Quantitect Reverse Transcription Kit (Qiagen) as per 
manufacturer’s instructions.  Briefly a genomic DNA elimination reaction on ice using the 
TRIZOL extracted RNA (1 µg) followed by a reaction containing reverse transcription 
reaction components was carried out.  Samples were incubated for 15 min at 42 °C and 
then 3 min at 95 °C to inactivate reverse transcriptase.  cDNA was then stored at -20 °C 
until needed.   A PCR was carried out on the specific gene of interest using this cDNA.  
Each tube for PCR analysis was set up as outlined in Table 2.4. A list of human primers 
used in this study can be found in Table 2-2 and Table 2-3 and. 
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Table 2-2.  PCR Reaction (Volume per Microfuge Tube) 
Component 
Volume 
(µl) 
cDNA 2.5 
Promega Go Taq Polymerase 0.125 
Promega Go Taq 5X Colourless Buffer 5 
2 µM Forward Primer  1 
2 µM Reverse Primer  1 
2.5 µM dNTPs 1 
Water 14.375 
 
 
Table 2-3.  Human Primer Sets and Product Size 
Primer Name Sequence 
Product Size  
(bp) 
Siglec-7 FP GCAGTGCAGGAGGAAACTCGGG 
253 
Siglec-7 RP CCGTCTCAGCCGTGCCCTAA 
Siglec-9 FP CCCAGGAGAGGGCTTAGGGTGAA 
246 
Siglec-9 RP TAGGGGGTGTCCCCTGCTCACA 
GAPDH FP AGAAGGCTGGGGCTCATTTG 
300 
GAPDH RP AGGGGCCATCCACAGTCTTC 
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2.2.7 IVIS 
 
Nanoparticles were conjugated with the fluorochrome Rhodamine 6G at Dr. Chris 
Scott’s lab in QUB.  These tagged nanoparticles (Rho6G NPs) were resuspended in PBS 
then injected into pathogen free (SPF) mice at a concentration of 2 mg/mouse in a final 
volume of 400 µl.   
 The mice were split into 4 groups. In group 1, 4 mice were injected  
sub-cutaneously (sub-cut) with sialic acid coated NPs (Sia Rho6G) and one was injected 
with blank Rho 6G NPs; in group 2, 4 mice were injected intravenously (IV) with sialic acid 
coated NPs (Sia Rho6G) and one was injected with blank Rho 6G NPs; in group 3, 4 mice 
were injected intraperitoneally (IP) with sialic acid coated NPs (Sia Rho6G) and one was 
injected with blank Rho 6G NPs) and finally in group 4, 2 mice were injected 
intraperitoneally with 400 µL of PBS as controls for the entire study.   
 The mice were imaged at 6 hr, 24 hr, 48 hr and 72 hr on the IVIS imaging system at 
1-5 second exposures.  At 48 hrs, one IP injected mouse and one PBS control were 
sacrificed by CO2 exposure followed by cervical dislocation.  These mice were dissected 
and organs from each were placed on separate petri dishes for viewing on the IVIS.   
 No further movement of the nanoparticles was seen when the live mice were 
imaged at 72 hr and all remaining mice were sacrificed.  The IP and sub-cut injected mice 
were all dissected and internal organs were imaged. 
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2.2.8 Production of PLGA Nanoparticles: 
 
0.25 g of Polyvinyl Alcohol (PVA) was added slowly to 50 ml of diH2O on a heated 
plate and stirred continuously until dissolved to give a 0.5% solution of PVA.  This was 
then cooled to room temperature.  19 ml was added to a fresh beaker on a magnetic 
stirring plate. 0.1 g of poly(lactic-co-glycolic acid) (PLGA) was dissolved in 5 ml of 
dichloromethane (DCM) and 1 ml of the PVA solution was added to this and mixed by 
vortexing.  The PLGA/PVA solution was sonicated at 2 W for 2.5 minutes to form an 
emulsion.  This emulsion was added to the 19 ml of PVA on the stirrer and left for 
approximately 4 hr or until the DCM had evaporated.  
 The resulting solution was then pelleted in an ultracentrifuge for 18,000 rpm for 
10 mins.  The waste was aspirated and the pellet was washed in 2 ml of diH2O and ultra-
centrifuged at the same speed as before.  This was repeated three times.  
 Finally the pellet was resuspended in 1.5 ml of diH2O and frozen at -80 °C for up to 
4 hrs.  The frozen PLGA was then freeze-dried overnight.  
 On day two the freeze-dried particles are resuspended at a concentration of 
1 mg/ml in HPLC grade water and measure on the Malvern Zeta-Sizer to find the size and 
zeta-potential 
 The biotin labelled sialic acid, GD3, was then incubated with the PLGA 
nanoparticles resuspended in 720 µL diH2O or PBS at a concentrations of 16.5 µM and 
500 µM along with 4.5 mg/mL of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide and 
mixed gently at room temperature for 4 hours. Control tubes were also set up without 
GD3. 
 After mixing, the tubes were spun at 13,200 rpm for 10 minutes and washed 
3 times in PBS. The final pellet was resuspended in 1 mL PBS. This solution was frozen at  
-80 °C for 30 minutes and freeze-dried overnight. 
 The freeze dried pellets were resuspended in 100 µL of PBS and Streptavidin APC 
was added to the mix at concentrations of 1:50 and 1:20. Fluorescence to indicate GD3 
binding efficiency was checked on the flow cytometer. 
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2.2.9 Statistical Analysis 
 
Statistical analysis between groups was carried out using a two-tailed, type 2, student t-
test.  This compares the mean of both groups assuming equal variation between the 
groups.  The graphs are graphically represented as mean ± STDEV.  
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3. Results 
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3.1 Identification of Siglec-7 as a Potential Negative Regulator of Pro-Inflammatory 
Cytokines in SLE 
 
3.1.1 Siglec-7 and Siglec-9 mRNA levels are altered in SLE patient peripheral blood 
mononuclear cells. 
 
Siglec-E and its human orthologues, Siglec-7 and Siglec-9, are inhibitory receptors 
that work to shut off and limit inflammatory stimuli driven by TLR4 and 7 [32], [30], [30, 
43].  Interestingly, the production of pro-inflammatory cytokines in mice has been shown 
to lead to an increase in Siglec-E expression [32].  Since pro-inflammatory cytokines are 
over-produced in SLE patients, we first wanted to investigate whether or not the 
expression of the human orthologues of Siglec-E, Siglec-7 and Siglec-9, are altered in SLE 
patient immune cells compared to cells derived from healthy controls.  In order to do this 
we looked at Siglec-7 and Siglec-9 mRNA levels in human peripheral blood mononuclear 
cells (PBMCs) both in resting state and following TLR stimulation by real time polymerase 
chain reaction (qPCR).  Preliminary data from our lab shows that consistent with the 
enhanced levels of inflammatory cytokines observed in SLE patients [44] Siglec-7 and -9 
mRNA levels in resting PBMCs from SLE patients were reduced compared to healthy 
controls (Figure 3-1).   
 We next looked at the effect of TLR4 and 7 stimulation on Siglec-7 and -9 
expression in PBMCs derived from SLE patients and compared our results to expression 
levels in control PBMCs (Figure 3-2).  No significance was calculated on these experiments 
as only 2 patients and 2 healthy controls were studied.  Interestingly, when cells were 
stimulated with TLR4, and 7 ligands, LPS and Imiquimod, respectively, Imiquimod but not 
LPS caused a visible increase in Siglec-7 expression in patient PBMCs compared to PBMCs 
derived from healthy controls (Figure 3-2A).  Conversely, Imiquimod treatment led to a 
visible decrease in Siglec-9 expression in patient PBMCs compared to PBMCs derived from 
healthy controls.  LPS treatment showed no difference in Siglec-9 expression levels 
between patients and healthy controls (Figure 3-2B).  Thus when SLE patient cells are 
exposed to TLR7 ligands, known drivers of SLE pathogenesis, Siglec-7 levels become 
elevated whereas Siglec-9 levels decrease.  Therefore a strategy to stimulate Siglec-7 in 
order to enhance the negative regulation of TLR signaling may be effective in the 
treatment of SLE. 
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Figure 3-1.  Siglec-7 and Siglec-9 expression in resting SLE patient PBMCs compared to PBMCs derived 
from healthy controls.  PBMCs were isolated from 3 healthy controls and 3 SLE patients and plated at a 
concentration of 2 x 10
5
 cells/ml in a final volume of 2 ml in a 6-well plate.  The cells were left to rest 
overnight and harvested after 15 hrs. mRNA was isolated from the cells by Trizol extraction and Siglec-7 and 
-9 expression levels were measured by RT-PCR.  This is a representative graph of three experiments and 
relative fold increase (RFI) was obtained using the ddCt method. 
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Figure 3-2.  Siglec-7 and Siglec-9 levels in SLE patient PBMCs compared to PBMCs derived from healthy 
controls after stimulation with TLR 4 and 7 ligands LPS and Imiquimod, respectively.  PBMCs were isolated 
from 2 healthy controls and 2 SLE patients and plated at a concentration of  
1 x 10
6
 cells/ml in a final volume of 2 ml in a 6-well plate.  The cells were stimulated with LPS or Imiquimod 
overnight and harvested after 15 hrs. mRNA was isolated from the cells by Trizol extraction and Siglec-7(A) 
and -9 (B) expression levels were measured by RT-PCR.  Relative fold increase (RFI) was obtained using the 
ddCt method. 
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3.1.2 Investigation of Siglec-7 levels in primary monocytes from SLE patients 
compared to monocytes derived from healthy controls.  
 
In silico analysis using BioGPS suggests that monocytes have a high concentration 
of Siglec-7 on their surface in comparison to Siglec-9.  Given these results and our 
previous observation that Siglec 9 expression is decreased in SLE PBMCs following TLR7 
stimulation, we therefore decided to concentrate on Siglec-7 expression on monocytes by 
RT-PCR.  
 Again we looked at Siglec-7 levels in resting monocytes from SLE patients when 
compared to healthy controls (Figure 3-3A).  While not statistically significant, we observe 
a trend towards reduced expression in patients compared to healthy control, similar to 
that seen in PBMCs.  We then looked at expression levels after TLR stimulation, as before 
(Figure 3-3B).  Contradictory to what was seen in PBMCs, the patient monocytes showed 
a slight increase in Siglec-7 expression, which was evident but not statistically significant, 
in response to LPS but not Imiquimod compared to healthy controls.  
 Patient data indicates that none of the patients are in an active disease state 
however one set of monocytes came from a patient on immuno-suppressive drugs which 
may have contributed to its altered response to TLR stimuli and the large standard 
deviation seen in Figure 3-3.  
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Figure 3-3.  Siglec-7 mRNA levels in SLE patients compared to healthy control monocytes.  Monocytes 
were isolated from the PBMCs of 3 SLE patients and 3 healthy controls.  First the levels of mRNA were 
examined in resting monocytes from SLE patients and healthy controls (A).  Significance was calculated 
using a two tailed student’s t-test.  Monocytes from patients and controls were stimulated with LPS  
(100 ng/mL) and Imiquimod (IMQ) (5 mg/ml) (B).  RFI was obtained using the ddCt method. 
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3.1.3 Introduction of Immune Complexes derived from active SLE patient serum to our 
system as a stimulus for TLRs 7&9. 
 
The use of Imiquimod as a stimulus for TLR 7 may be considered too artificial to 
give us results that we would expect to see in patients so we developed and optimized a 
protocol to isolate immune complexes (ICs) from active SLE patient serum as an 
alternative method to stimulate TLRs 7 & 9. 
 The protocol is described in detail in the materials and methods section.   
Figure 3-4A shows the A280 curve obtained following loading of the serum onto the 
column and to monitor removal of unbound protein during the wash steps.  The A280 
indicates the level of protein present in each sample.  The initial levels are high as the 
unbound protein is washed from the column and decreases with each wash step.  A280 
levels are converted to give protein levels in mg/mL. 
 After the column has been washed clean, a low pH solution is added to elute the 
IgG bound to the column.  Figure 3-4B shows the A280 levels in the eluates tested; again 
this has been converted to represent protein levels in mg/mL.  The levels are low initially 
but peak after 2–3 washes as the immune complexes are eluted off then decrease again.  
Eluates with a protein level ≥ 0.5 mg/mL were retained a concentrated into aliquots at  
5 mg/mL. 
 The concentrated ICs were then validated before use.  This was done by adding ICs 
at varying concentrations (100 µg/mL, 500 µg/mL and 1mg/mL) to primary PBMCs 
isolated from healthy donors.  The cells were also stimulated with 100 ng/mL LPS to 
compare their response.  The cells were left for 15 hrs then the supernatant was 
harvested and tested by ELISA for TNFα levels.  ICs at a concentration of 500 µg/mL 
generated the greatest response (Figure 3-4C) so this was the concentration used in all 
experiments.  
These concentrations varied significantly between patients therefore the graphs below 
were created from one set of results but are representative of all results. The immune 
complexes purified for this project were also used in other on-going experiments in the 
lab to mimic flare conditions in SLE. Results published from these studies demonstrate the 
effectiveness of IC to activate SLE immune cells and mimic flares [5-7] 
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Figure 3-4.  Isolation, concentration and validation of immune complexes from active SLE patient serum.  
(A) After active patient serum is added to the protein G column, the column is washed with Tris and this 
wash is collected in 1 mL samples.  After each sample is taken, the A280 is calculated to obtain the amount 
of protein that has been washed off.  Once the levels of protein have dropped to ≤ 0.2 mg/mL the immune 
complexes can be collected.  (B) The bound immune complexes are flushed from the column with a low pH 
solution in 1 mL aliquots and the A280 levels are measured to obtain protein levels.  Eluates with a 
concentration of ≥ 0.5 mg/mL are retained and concentrated.  (C) PBMCs were isolated from healthy donors 
and seeded at a concentration of 2 x 105 cells/mL in 200 µL and were left untreated or stimulated with  
LPS (100 ng/mL), Imiquimod (5 mg/mL) or ICs (100 µg/mL, 500 µg/mL and 1 mg/mL).  The cells were left for 
15 hr and the supernatant was then harvested and tested by ELISA for TNFα levels. The graphs above are 
results from one batch of ICs and the experiment was carried out in triplicate wells.  
49 
 
We next added the ICs to PBMCs from both SLE patients and healthy controls and 
compared the levels of Siglec-7 & -9 in both (Figure 3-5A).  What we saw was that both 
Siglec-7 & -9 levels are significantly lower in PBMCs from SLE patients compared to those 
derived from healthy donors after ICs stimulation.  
 We then went on to look at the Siglec-7 expression in monocytes from SLE 
patients compared to healthy controls (Figure 3-5B).  The expression levels are lower in 
patients as we saw in the PBMCs.  The difference is not significant but it is approaching 
significance so with more samples we would possibly see a similar result as that which we 
saw in PBMCs, again fitting with our theory described above.   
 After determining the difference between patients and controls at a molecular 
level we then went on to use the immune complexes to study the ability of our 
nanoparticles to affect immune responses at a protein level. 
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Figure 3-5.  Siglec-7 & -9levels in PBMCs and Siglec-7 levels in monocytes following IC stimulation for 15 
hrs.  PBMCs were isolated from 2 healthy controls and 2 SLE patients and plated at a concentration of 1 x 
10
6
 cells/mL in a final volume of 2 mL in a 6-well plate.  The cells were stimulated with immune complexes  
(500 µg/mL) overnight and harvested after 15 hrs.  mRNA was isolated from the cells by Trizol extraction 
and Siglec-7 and -9 expression levels were measured by RT-PCR (A).  Monocytes were isolated from the 
PBMCs of SLE patients and healthy controls and set up and stimulated as above (B).  Siglec-7 expression was 
calculated by RT-PCR. RFI was obtained using the ddCt method and significance was determined by 
student’s t-test. 
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3.2 Investigating the localization of Sialic Acid Coated nanoparticles  
(Sia NPS) in mice and the effect of Sia NPs on pro-inflammatory cytokine 
production in human cells 
 
3.2.1 Validation of the negative regulation of pro-inflammatory cytokines by Sia NPs in 
murine peritoneal macrophages 
 
The following experiments were carried out by Dr. Shaun Spence in Queen’s University 
Belfast to characterize the nanoparticles before they were sent to us. Peritoneal 
macrophages from wild type mice were extracted and stimulated cells with LPS to induce 
TNFα production via TLR4.  The potential inhibitory properties of the Sialic acid 
conjugated NPs (Sia NPs) were examined by the addition of either the blank particles with 
no sialic acid conjugated or particles coated with sialic acid as shown in Figure 3-6A and 
(B), respectively.   
 Figure 3-6A shows an expected significant increase in TNFα production following 
LPS stimulation.  When the blank nanoparticles are added to the cells on their own a 
small but non-significant induction of TNFα is observed and when they are added with LPS 
they also show no significant effect compared to LPS stimulation on its own.  However, 
Figure 3-6B shows the effects after the sialic acid conjugated particles are added.  The 
same TNFα production can be seen after LPS stimulation and, again, the conjugated 
particles show no significant effect when added on their own to the cells, but when both 
LPS and the Sia NPs are added to the cells a significant decrease can be seen in TNFα 
production, indicating that the NPs are negative regulators of TNFα production in murine 
peritoneal macrophages responding to LPS.   
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Figure 3-6.  The effect of Sia NPs on LPS induced TNFα production in murine peritoneal 
macrophages.  Peritoneal macrophages were isolated from wild type C57Bl6 mice. A shows the 
cells incubated alone (lane 1) with LPS (lane 2) with nude nanoparticles (lane 3) and with both 
LPS and nude particles (lane 4). B shows the cells incubated alone (lane 1), with LPS (lane 2), with 
sialic acid conjugated nanoparticles (lane 3) and with both LPS and sialic acid conjugated 
nanoparticles (lane 4). TNFα production was measured by ELISA. Experiments were carried out in 
triplicate.  
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3.2.2 Localization of Sia NPs in mice after sub-cutaneous, intravenous and 
Intraperitoneal injection. 
 
After it had been proven that the Sia NPs could inhibit TNFα production in mice, 
we next wanted to see where these nanoparticles were localizing in the mice following 
different routes of administration. In order to see this, nanoparticles were conjugated 
with the fluorochrome Rhodamine 6G.  These tagged nanoparticles (Rho6G NPs) were 
then injected into the mice at a concentration of 2 mg/mouse in a final volume of 400 µl.  
Injections were given in three ways; sub-cutaneously (sub-cut), intravenously (IV) and 
intraperitoneally (IP).  There were five mice per group (4 x Sia Rho6G and 1 x blank 
Rho6G) and two PBS controls for the entire experiment.  They were imaged at 6 hr, 24 hr, 
48 hr and 72 hr on the IVIS imaging system.  
 At 6 and 24 hr, no movement of the particles from the site of injection could be 
seen in any of the groups (data not shown). 
 When imaging the mice at 48 hr (Figure 3-7) we could see a high concentration of 
particles in the sub-cutaneous and IP injected mice (indicated by arrows in A and C).  The 
IP image taken is a 1 second exposure (C).  The level of fluorescence seen in IV injected 
mice indicated that there was a high concentration of particles in the area of 
administration so we chose this mouse to dissect along with a PBS control.  The IV 
injected mice showed no fluorescence not seen on the PBS control, (B), so we concluded 
that this was not a successful method for injecting these particles.  
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Figure 3-7.  Localization of Rho6G particles in mice after 48hr.  SPF mice were imaged at 48 hr after 
injection with 2 mg/mouse of Rhodamine 6G nanoparticles.  One mouse in each group was injected with 
unconjugated particles (lane 1) and 4 mice were injected with sialic acid conjugated particles (lanes 2–5).  
There were two PBS injected mice used as an experimental control (lane 6). (A) shows the group of mice 
injected sub-cutaneously in a 5 second exposure image.  The arrow indicates an area of fluorescence that 
was higher than the background levels. (B) shows the mice that were injected intravenously (tail-vein) in a 5 
second exposure image and (C) shows the mice that were injected intraperitoneally in a 1 second exposure 
image.  Again the green arrow indicates an area of higher fluorescence than background levels. 
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When we dissected the IP injected mouse (Figure 3-8) we saw some fluorescence 
in the internal organs (A).  To investigate further we extracted the organs and viewed 
these on a petri-dish (B).  Figure 3-8B shows on the left organs taken from the PBS control 
mouse and on the right are the organs taken from the Sia NP Rho6G injected mice.  On 
careful inspection we saw low levels of fluorescence in the heart, liver and thymus and a 
high level of fluorescence in the kidney.  We considered that that the fluorescence seen 
at the base of the tail in almost all of the mice in Figure 3-7 was as a result of the 
nanoparticles being excreted and this can be confirmed by the high level of fluorescence 
seen in the kidneys (Figure 3-9).  
 The experiment was terminated at 72 hr and all remaining mice were sacrificed.  
The IP and sub-cut injected mice were all dissected but no fluorescence could be seen in 
the internal organs (data not shown). 
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Figure 3-8.  Intraperitoneally injected mouse and PBS control mouse dissected at 48hr post injection.  Two 
mice were injected intraperitoneally at time = 0 hr, one with Rhodamine 6G tagged sialic acid conjugated 
nanoparticles and one with PBS as a control.  At t = 48 hr these mice were culled by CO2 exposure followed 
by cervical dislocation and were then dissected (A).  The PBS injected mouse can be seen on the left and the 
nanoparticle injected mouse is on the right in both pictures in (A).  The major organs were then removed 
and viewed on two petri-dishes. (B) The organs are labeled as follows; 1 = Spleen, 2 = Kidneys, 3= Liver,  
4 = Lungs, 5 = Thymus and 6 = Heart.  The PBS control is on the left and the organs from the nanoparticle 
injected mouse are on the right.  The green arrows here are pointing at unavoidable high background 
fluorescence caused by imprints on the dish.  This background was taken into consideration when 
measuring the fluorescence seen in the organs. 
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Figure 3-9.  Fluorescence of individual organs from PBS injected mouse and from intraperitoneally 
injected Sia NP mouse at 48hr.  This shows an enlarged image of the organs from Figure 2.2.2 (B). Smaller 
areas of fluorescence are indicated with green arrows. These images were taken with a 1 second exposure 
time at the highest resolution. 
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3.2.3 Effect of Sia NPs on pro-inflammatory cytokine production in human PBMCs  
 
SiaNPs had been shown to reduce the production of TNFα in murine macrophages 
based on the results from our collaborators in QUB so next we wanted to see if they 
would have the same effect in human cells. In order to do this we carried out a similar 
experiment looking at pro-inflammatory cytokine levels in human peripheral blood 
mononuclear cells (PBMCs) which we stimulated with ligands for TLR4 (LPS) and for TLRs 
7 and 9 (Imiquimod and CpG DNA, respectively) since they are more relevant in SLE. 
 
3.2.3.1 The effect of Sia NPs on TNFα production in human PBMCs 
 
First we looked at TNFα, a key proinflammatory cytokine whose production in 
response to LPS was previously shown to be inhibited in the presence of Sia NPs in murine 
peritoneal macrophages.  Figure 3-10A shows PBMCs in a resting state after overnight 
incubation with Sia NPs and blank NPs.  Interestingly, we can see that the Sia NPs alone 
are causing an unexpected increase in TNFα in the resting cells.  This is not seen with the 
blank NPs.  Referring back to Figure 3-6A a very slight increase can be seen with the 
nanoparticles on their own; however, these are the blank nanoparticles and not the Sia 
NPs.  We can deduce from this that the cells are eliciting a significant pro-inflammatory 
response to the Sia NPs alone.  We took this into consideration when analysing further 
data.  Figure 3-10B shows the production of TNFα in PBMCs after TLR stimuli are added 
along with the NPs.  With LPS stimulation we see a significant inhibition in TNFα 
production when Sia NPs are present.  This is similar to the result seen in the murine 
peritoneal macrophages.  As there is no TNFα induction when TLRs 7 and 9 are stimulated 
with Imiquimod and CpGC respectively, we therefore cannot see any effect of the 
nanoparticles, except to say that the Sia NPS consistently induce production of TNFα on 
their own.    
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Figure 3-10.  The effect of Sia NPs on TNFα production in human PBMCs.  PBMCs were isolated from the 
whole blood of a healthy donor and were then incubated with TLR stimuli and nanoparticles.  (A) shows the 
PBMCs in a resting state after overnight incubation with Sia NPs (SNP) (150 µg/mL) or blank NPs (150 
µg/mL).  (B) shows PBMCs after overnight night incubation with SIa NPs or blank NPs in addition to the 
TLR4, 7 and 9 stimuli LPS (100 ng/mL), Imiquimod (10 µg/mL) and CpGC (5 µM) respectively.  TNFα levels 
were measured by ELISA, errors were determined by standard deviation and significance was determined 
by two tailed student’s t-test. All graphs represent n=3. 
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3.2.3.2 The effect of Sia NPs on IL-6 production in human PBMCs 
 
We next looked at the pro-inflammatory cytokine Interleukin-6 (IL-6).  Figure 3-11 
part (A) shows IL-6 production by resting PBMCs that have been incubated overnight with 
either Sia NPs or blank NPs.  A significant increase can be seen when the Sia NPs are 
added to the cells.  This is not seen with the blank NPs, thus confirming the cells’ response 
to the sialic acid conjugated to the particles that we saw with TNFα. 
 Part (B) of Figure 3-11 shows the IL-6 production by PBMCs after overnight 
stimulation with TLR agonists LPS, Imiquimod and CpG in addition to incubation with Sia 
NPs or blank NPs.  The Sia NPs cause a significant inhibition of IL-6 production following 
TLR4 stimulation by LPS.  This is similar to the inhibition of TNFα seen with TLR4 
stimulation and Sia NPs.  Interestingly, when we looked at IL-6 production after 
Imiquimod stimulation of TLR7 we see a significant and unexpected increase after the 
addition of Sia NPs, suggesting that the Sia NPs are enhancing the Imiquimod induced 
effect.  CpG had no significant effect on IL-6 production in the presence or absence of Sia 
or blank nanoparticles. 
 
Figure 3-11.  The effect of Sia NPs on IL-6 production in human PBMCs.  PBMCs were isolated from the 
whole blood of a healthy donor and were then incubated with TLR stimuli and nanoparticles. (A) shows the 
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PBMCs in a resting state after overnight incubation with Sia NPs (SNP) (150 µg/mL) or blank NPs 
(150 µg/mL).  (B) shows PBMCs after overnight night incubation with SIa NPs or blank NPs in addition to the 
TLR4, 7 and 9 stimuli LPS (100 ng/mL), Imiquimod (10 µg/ml) and CpG (5 µM) respectively.  IL-6 levels were 
measured by ELISA, errors were determined by standard deviation and significance was determined by two 
tailed student’s t-test. All graphs represent n=3. 
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3.2.4 The effect of Sia NPs on RANTES production in human PBMCs 
 
Finally, we looked at production of the chemokine RANTES (CCL5) in PBMCs.  
When we looked at the levels in of this cytokine PBMCs, initially we saw the same 
increase in response to Sia NPs as we did with TNFα and IL-6 in resting cells Figure 3-12 A.  
This overall induction of pro-inflammatory cytokines by the Sia NPs in resting cells forced 
us to draw the conclusion that, whilst these nanoparticles can significantly inhibit the 
inflammatory response to TLR4 stimulation, they can induce an inflammatory response on 
their own in resting cells.  
 We then looked at RANTES production in PBMCs after overnight incubation with 
TLR stimuli LPS, Imiquimod and CpGC, Figure 3-12B.  Again, we saw a significant inhibition 
in RANTES production after TLR4 stimulation and incubation with Sia NPs with LPS.  
However in this case the blank nanoparticles also had the same effect.  Neither set of 
nanoparticles showed any effect on RANTES levels after stimulation with Imiquimod or 
CpGC.  
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Figure 3-12.  The effect of Sia NPs on RANTES production in human PBMCs.  PBMCs were isolated from the 
whole blood of a healthy donor and were then incubated with TLR stimuli and nanoparticles.  (A) shows the 
PBMCs in a resting state after overnight incubation with Sia NPs (SNP) (150 µg/ml) or blank NPs (150 
µg/ml).  (B) shows PBMCs after overnight night incubation with SIa NPs or blank NPs in addition to the TLR4, 
7 and 9 stimuli LPS (100 ng/ml), Imiquimod (10 µg/ml) and CpGC (5 µM) respectively.  RANTES levels were 
measured by ELISA, errors were determined by standard deviation and significance was determined by two 
tailed student’s t-test.  All graphs represent n=3.  
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3.2.5 The Effect of Sia NPs on Pro-Inflammatory Cytokine Production in Human 
Monocytes 
 
Siglec-7 expression in pure monocytes has been shown to be different to the 
results seen from a mixed population such as PBMCs [45], so we decided to isolate 
monocytes and test the particles on these to investigate whether or not they had any 
therapeutic potential.  There were only enough particles to test each cytokine twice and 
so all results are shown below.  In part (B) of each set of results, immune complexes (ICs) 
isolated from active SLE patient serum has been substituted for CpG to determine the 
effect of a more biologically relevant stimulus. 
 
3.2.5.1 TNFα levels in monocytes after Sia NP treatment 
 
We looked at TNFα first so that we could make direct comparisons to the tests in 
murine peritoneal macrophages and human PBMCs.  In the first instance we added TLR4, 
7 and 9 stimuli LPS, Imiquimod and CpG, Figure 3-13 (A).  Again, we saw an indication of 
stimulation with the Sia NPs on their own but this was not significant.  We saw no 
significant differences between the cells’ responses to any of the TLR stimuli on their own 
compared to the response to TLR stimulation together with Sia NPs or blank NPs, thus 
suggesting that the nanoparticles were not functioning in the same way as they did in the 
PBMCs.  
 Interestingly, when we tried this experiment a second time we saw varying results.  
The stimulus CpGC was replaced with ICs (B).  This time we saw the initial increase in the 
untreated cells when NPs were added, however, we saw it with both Sia NPs and blank 
NPs, suggesting that it was not the sialic acid that was causing this effect.  We did see the 
expected decrease with Sia NPs after TLR4 stimulation but, again, we also saw this with 
blank NPs.  And, while we saw a significant increase in TNFα with the addition of IgG, this 
response was exacerbated when the Sia NPs and blank NPs were added.   
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Figure 3-13.  The effect of Sia NPs on TNFα production in human monocytes.  Monocytes were isolated 
from human PBMCs and incubated overnight with TLR stimuli and either Sia NPs (SNP) (150 µg/ml) or blank 
NPs (150 µg/ml).  (A) shows the results of one experiment in triplicate wells. TLRs 4, 7 and 9 were 
stimulated with stimuli LPS (100 ng/ml), Imiquimod (10 µg/ml) and CpGC (5 µM) respectively.  (B) shows the 
results of the second attempt at this experiment in triplicate wells.  Immune complexes (IgG) (500 µg/ml) 
were substituted for CpGC to stimulate TLRs 7/9.  TNFα levels were measured by ELISA.  Errors were 
determined by standard deviation.   
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3.2.5.2 IL-6 levels in monocytes after Sia NP treatment 
 
When we examined IL-6 levels in monocytes we again saw varying results over 
two experiments.  Initially we saw the Sia NPs causing a significant increase in IL-6 
production after Imiquimod stimulation of TLR7, Figure 3-14A.  This is similar to what we 
saw in the PBMCs (Figure 3-11B).  However, we did not see the inhibition we would 
expect to see after addition of Sia NPs and TLR4 stimulation with LPS.  We saw a non-
significant increase in IL-6 in the untreated monocytes.  
 When we repeated this experiment we saw a significant increase in IL-6 in the 
resting monocytes when the nanoparticles were added.  Again, we saw this with both Sia 
NP and blank NPs so we cannot determine that this response is because of the sialic acid.  
The nanoparticles had no effect when added to the cells with LPS, Imiquimod or IgG.  
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Figure 3-14.  The effect of Sia NPs on IL-6 production in human monocytes.  Monocytes were isolated from 
human PBMCs and incubated overnight with TLR stimuli and either Sia NPs (SNP) (150 µg/ml) or blank NPs 
(150 µg/ml).  (A) shows the results of one experiment in triplicate wells.  TLRs 4, 7 and 9 were stimulated 
with stimuli LPS (100 ng/ml), Imiquimod (10 µg/ml) and CpGC (5 µM) respectively.  (B) shows the results of 
the second attempt at this experiment in triplicate wells.  Immune complexes (IgG) (500 µg/ml) were 
substituted for CpGC to stimulate TLRs 7/9.  IL-6 levels were measured by ELISA.  Errors were determined by 
standard deviation.   
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3.2.5.3 RANTES levels in monocytes after Sia NP treatment 
 
Finally we looked at RANTES production in monocytes after incubation with Sia 
NPs.  In the first experiment we saw similar results to those we saw in PBMCs  
(Figure 3-12B).  There was an insignificant increase in RANTES production in untreated 
cells after Sia NPs were added.  There was a significant inhibition of LPS induced RANTES 
production following the addition of Sia NPs, Figure 3-15A.  The increase in production 
seen after Imiquimod stimulation was significantly enhanced following Sia NP.  There was 
no change in RANTES levels following CpGC stimulation with or without NPs.  
 The second time this experiment was carried out we saw some similarities  
Figure 3-15B.  Again, we saw an increase in the RANTES levels of untreated monocytes 
following incubation with Sia NPs; however this was a significant increase.  We also saw a 
significant reduction in LPS induced RANTES production following incubation with Sia NPs; 
however, the blank NPs were also causing a decrease. Similarly, the Sia NPs caused a 
significant decrease in IgG induced RANTES production. 
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Figure 3-15.  The effect of Sia NPs on RANTES production in human monocytes.  Monocytes were isolated 
from human PBMCs and incubated overnight with TLR stimuli and either Sia NPs (SNP) (150 µg/ml) or blank 
NPs (150 µg/ml).  (A) shows the results of one experiment in triplicate wells. TLRs 4, 7 and 9 were 
stimulated with stimuli LPS (100 ng/ml), Imiquimod (10 µg/ml) and CpGC (5 µM) respectively.  (B) shows the 
results of the second attempt at this experiment in triplicate wells.  Immune complexes (IgG) (500 µg/ml) 
were substituted for CpGC to stimulate TLRs 7/9. RANTES levels were measured by ELISA.  Errors were 
determined by standard deviation.  All graphs represent n=3 
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3.3 Development of a Novel Sialic Acid Activity Assay in Primary Human Cells 
 
3.3.1 Design and development of a novel sialic acid activity assay 
 
Given the heterogeneity of results and lack of significant inhibition of either TLR-7- 
or IC-driven production of TNF, IL-6 or RANTES, we set out to screen for additional sialic 
acids that might have inhibitory potential in this respect. As previously mentioned, Siglecs 
have higher affinity for certain α-linkages in sialic acids. Siglec-7’s has a high affinity for α-
2,8 linkages, which  was the nature of the linkage of the sialic acid on our original 
particles.  We know that Siglecs have potential as inhibitory receptors due to the ITIM 
found in their tail and so wanted to pursue this by testing an array of sialic acids that 
could potentially bind to and activate Siglec-7.  
 We received 27 biotin-labeled sialic acids with varying α-linkages from the 
Consortium for Functional Glycomics (CFG; http://www.functionalglycomics.org/).  By 
incubating these sialic acids on Streptavidin-coated plates they would bind via their biotin 
tag.  We could then add monocytes and stimulate as before and look for any possible 
inhibition caused by the sialic acids. 
 We initially looked at TNFα levels to test our hypothesis based on the ability of the 
nanoparticles seen in Section 3.2.  When we tried this first on the Streptavidin-coated 
plates, the monocytes became activated as shown by the high baseline expression of TNF-
a observed in the absence of ligand , Figure 3-16A ,and so we needed to optimize this 
assay in order to reduce the high background.  The experiment was repeated using 
Neutravidin-coated plates since Neutravidin is deglycosylated and therefore potentially 
less immunoreactive. This also gave us very high background, Figure 3-16B.  In each case 
we utilized various blocking agents (sterile water, PBS, 5% BSA, human IgG) to attempt to 
reduce the background but we unsuccessful (data not shown).  We finally tried this on 
high bind NUNC™ MaxiSorp™ 96 well plates, Figure 3-16C.  We tried an additional step on 
the NUNC plates where we blocked with sterile water, PBS, 5% BSA, human IgG, no block 
and no wash, we also included one of our sialic acids as a control.  We successfully 
lowered the background levels by using only PBS and sterile water for dilution of buffers 
but blocking of the NUNC™MaxiSorp™ plate was not necessary as shown in Figure 3-16D.
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Figure 3-16.  Optimization of Sialic Acid Assay.  One Streptavidin-coated plate (A), one Neutarvidin-coated 
plate (B) and one NUNC™ Maxisorp™ plate (C) were incubated with 60 pM of sialic acids per well overnight 
at 4 °C.  Each plate was washed three times with PBS and blocked in 5% BSA for 1 hr.  The plate was washed 
three more time in PBS and Monocytes were added at 2 x 10
5
 cells/mL and allowed to rest for 1hr at 37 °C 
before stimulation with LPS (100 ng/mL), Imiquimod (10 µg/mL) and IgG Immune Complexes from active 
SLE patient serum (500 µg/mL). (A), (B) and (C) show the basal TNFα produced by the monocytes in the 
wells with no sialic acid from these plates.  (D) shows the results of the optimization carried out on a 
NUNC™ Maxisorp™ plate.  The wells were blocked with either sterile water, PBS, 5% BSA or human IgG.  
Each of these wells were then washed three times with PBS before adding monocytes, we also tried no 
block at all and no additional washing after the sialic acids had been washed away.  Sialic acid 2 (Sia 2) was 
added to one set of wells as a control.  200 µL/well of monocytes were then added at a concentration of  
2 x 10
5
 cells/mL and stimulated with LPS (100 ng).  All optimization was carried out in triplicate and errors 
were calculated by standard deviation. 
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 After optimizing the assay on the NUNC™ Maxisorp™ plates and reducing the 
background seen previously, we then continued testing the sialic acids supplied by the 
CFG.  Where we had two or more sialic acids that were functionally or structurally very 
similar we looked at just one and omitted the others.  This left us with 23 sialic acids to 
test.  Of these 23 only sialic acids 2 and 8 gave us consistently significant results therefore 
only selected results are displayed below to highlight this.  Sialic acids are referred to 
numerically here for graphical purposes, for their full titles please refer to Table 3-1.   
 The sialic acids were added at a concentration of 60 pM/well and incubated 
overnight.  The plates were not blocked as shown in Figure 3-16D and monocytes were 
added and stimulated with LPS, Imiquimod and IgG immune complexes from active SLE 
patient serum.  The results of these stimulations are shown below (Figure 3-17) in % 
activity form i.e. the cytokine production in monocytes with no sialic acid was considered 
100% activity and any changes seen in the other samples were considered to be as a 
direct effect of the sialic acid on the cells.  
 Figure 3-17A shows TNFα production in monocytes following stimulation with 
immune complexes.  A significant decrease can be seen when the monocytes were 
incubated with sialic acid 8 (Sia8).  (B) shows IL-6 production in monocytes after immune 
complex stimulation and, again, Sia 8 is showing a significant decrease, we also see Sia 2 
causing a slightly less significant inhibition in IL-6 production.  (C) shows RANTES 
production after stimulation with immune complexes and here we see Sia 8 again 
showing significant inhibition.  Finally (D) shows RANTES production following Imiquimod 
stimulation.  Here we see both Sia 2 and Sia 8 showing significant inhibition of RANTES 
production.  
 The consistent inhibition of cytokine production seen with Sia 8 lead us to 
conclude that this sialic acid could possibly be acting via Siglec-7 on monocytes to induce 
an inhibitory response to stimulation with TLR agonists.  
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Table 3-1.  List of Biotin Labeled Sialic acids Supplied by the Consortium for Functional 
Glycomics 
RCSI 
Reference 
CFG Catalogue 
No. 
Mol. Weight 
Common 
Name 
α-linkage 
1 B83 1151.26 3'SL 2-3 
2 B85 1192.26 3'SLec 2-3 
3 B86 1151.26 6'SL 2-6 
4 B87 1192.26 6'SLN 2-6 
5 B89 1167.21 3'S(Gc)L 2-3 
6 B90 1208.26 3'S(Gc)LN 2-3 
7 B93 1208.26 6'S(Gc)LN 2-3 
8 B107 1420.5 GD3 2-8 
9 B108 1128.5 GT3 2-8 
10 B157 1316.2 3'SLex 2-3 
11 B167 2390.3 3'S-Tri-Lex 2-3 
12 B174 1338.4 3'SLea 2-3 
13 B177 1332.42 GM2 2-3 
14 B178 1535.1 3'S-Di-LN 2-3 
15 B179 1535.1 6'S-Di-LN 2-6 
16 B184 1669.9 GD2 2-8 
17 B194 1923.5 3'S-Tri-LN 2-3 
18 B202 1494.5 GM1 2-3 
19 B204 1371.5 CT/Sda 2-3 
20 B273 1211.34 3'SLDN 2-3 
21 B274 1211.34 6'SLDN 2-6 
22 B295 1656.71 SSEA-4 2-3 
23 B296 1819.89 3'S-Di-Lex 2-3 
24 B297 1541.6 3'SLecLN 2-3 
25 B298 1829.79 GD1a 2-3 
26 B300 1849.88 3'SLeaLex 2-3 
27 B303 1557.6 3'SLN-Lec 2-3 
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Figure 3-17.  Sialic Acid Assay in monocytes on NUNC™ Maxisorp™ plates.  Plates were coated with 
60 pM/well of the sialic acids and incubated overnight at 4 °C.  The plates were washed with sterile PBS 
three times and 200 µL/well monocytes were added at a concentration of 2 x 10
5
 cells/mL.  The cells were 
rested at 37 °C for 1 hr and then stimulated with LPS (100 ng/mL), Imiquimod (10 µg/mL) and IgG immune 
complexes from active SLE patient serum (500 µg/mL).  The results were graphed as % activity, where 
cytokine production by monocytes with no sialic acid is considered 100% activity.  (A) shows % activity of 
TNFα production after IgG stimulation.  (B) shows % activity of IL-6 production after IgG stimulation.  (C) 
shows RANTES production after IgG stimulation and (D) shows RANTES production after Imiquimod 
stimulation.  All cells were stimulated overnight and cytokine levels were measured by ELISA.  Errors were 
calculated using standard deviation and significance was determined using a student’s t-test.  All graphs 
represent n=3 
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3.4 Production of PLGA Nanoparticles 
 
We have now identified Sia 8 from our assay as the ganglioside GD3, a known ligand 
for Siglec 7 [29].  We also know that sialic acid conjugated nanoparticles that could inhibit 
the inflammatory response in murine cells were not functioning in the same manner in 
human cells so we began to optimize the production of our own PLGA nanoparticles to 
which we would conjugate GD3.  Due to time constraints this process was never fully 
optimized but the preliminary results are shown below.  
 0.5% PVA was dissolved and combined with dissolved PLGA.  The solution 
emulsified and freeze dried to give us PLGA nanoparticles.  These were tested on the Zeta 
sizer to obtain the size and zeta potential of the particles.  The results are shown in  
Error! Reference source not found..  The desired size was ≤ 500 nm and the 
recommended polydispersity index (PDI) was ≤ 0.7.  Two batches were made (Batch 1 and 
Batch 2) and Batch 1 was too large (average 1370 nm) and the average PDI was 0.784 so 
these were not used again. Batch 2 were an appropriate size (average 365 nm) and had 
an average PDI of 0.395, which is within the acceptable limit.  
We then attempted to conjugate Batch 2 to our GD3 sialic acid at a concentration 
of 16.5 µM by incubating them with 1-ethyl-3-(3-dimethyaminopropyl)-carbodiimide 
(EDC).  To assess the efficiency of the conjugation we incubated these with a Streptavidin 
APC antibody at 1:50 concentration and looked for fluorescence by flow cytometry.  No 
fluorescence was seen.  The antibody concentration was increased to 1:20 and still no 
fluorescence was seen. 
 The experiment was repeated with the GD3 concentration increased to 500 μM 
and the antibody concentration remained at 1:20.  As with the previous attempt no 
conjugation of GD3 to the NPs was observed and time constraints prevented further 
trouble-shooting and development of this technique. 
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4. Discussion 
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4.1 Targeting Murine Siglec-E with Sialic Acid coated Nanoparticles  
 
The murine sialic acid receptor, Siglec-E, is a cell-surface receptor that contains an 
immune receptor tyrosine-based inhibitory motif (ITIM) [46]. Similar to human Siglec-7, it 
is expressed on peritoneal macrophages, dendritic cells and mature NK cells [47] thus 
giving us a viable animal model in which to study the inhibitory properties of Siglec-7. 
 Boyd et al showed that Siglec-E expression is upregulated and phosphorylated in a 
MyD88 dependent manner [32]. They also that it can interact with Src homology 2 
domain containing protein tyrosine phosphatases 1 and 2 (SHP1 and SHP2) to negatively 
regulate production of the proinflammatory cytokine TNFα. 
 The therapeutic potential of Siglec-E as a negative regulator of a lupus-like 
proinflammatory response led our collaborators in Queen’s University Belfast (QUB) to 
develop nanoparticles that could target Siglec-E as ligands and activate it as a negative 
regulator. Unpublished data (Figure 3-6) from experiments carried out by Dr. Shaun 
Spence in QUB, showed that these particles were capable of inhibiting TNFα production in 
murine peritoneal macrophages following LPS stimulation.  
 The first stage of this study was to look at the biodistribution of these particles in 
mice in vivo using fluorescently tagged nanoparticles. Nanoparticles are increasingly being 
used as a method of drug delivery as they are biodegradable and biocompatible and do 
not illicit a strong immunological response [48]. Studies have shown that delivery method 
can have a major influence on biodistribution of the particles [49], [50], [51]. In a similar 
biodistribution study [52], injection of mice via three individual injection routes as carried 
out in our analysis (sub cutaneously, intravenously and intraperitoneally) resulted in all 
cases in increased levels of nanoparticles in the liver, spleen and kidneys.  Whilst we 
expected to see a high percentage of our particles localizing in the kidney and liver, we 
also saw a significant concentration of nanoparticles in the thymus, an observation that 
was not previously observed in similar studies.  Yu et al conducted a study published 
evidence of Siglec-E expression in all three of the organs shown to accumulate 
nanoparticles in our experiment [46]. While this could suggest that the nanoparticles are 
localizing where Siglec-E can be found in high concentrations, it further studies would 
need to be conducted to verify this hypothesis. 
78 
 
 
4.2 Siglec-7and -9 as Potential Therapeutic Targets in SLE  
 
 Siglecs-7 and -9 are well characterized receptors, known to have inhibitory 
properties, with the presence of an ITIM in their cytosolic tails [53], [54], [55].  Because of 
their homology with murine Siglec-E (Figure 1-4), these two receptors were chosen as 
targets for our nanoparticles.  Both Siglec-7 and Siglec-9 are capable of negatively 
regulating T-Cell receptor signaling [56] and so the expression of both receptors at a 
genetic level in SLE patients was investigated.   
 First we investigated Siglec expression.  SLE patients displayed lower levels of 
expression of Siglec-7 and Siglec-9 when compared to healthy controls in resting PBMCs 
(Figure 3-1).  It is possible that this low level of expression means that SLE patients are 
unable to effectively inhibit the over-production of inflammatory cytokines associated 
with this disease.   
 We then mimicked cellular activation of PBMCs from patients and controls using 
TLR4 and TLR 7 ligands, LPS and Imiquimod, respectively.  A significant increase in Siglec-7 
in patient cells was observed when compared to controls (Figure 3-2).  This suggests that 
while patients are capable of up-regulating the Siglec (as seen with Siglec-E) it may not 
function as it would in a healthy individual.  There are many suggestions in the literature 
that defects in negative regulars of inflammation may contribute to autoimmunity. For 
example the cell surface receptor SIGGIR is a negative regulator of TLR signaling, which 
when deleted in mice, results in the overproduction of proinflammatory cytokines and a 
lupus-like disease [18, 19, 57]. In addition the ratio of immunoglobulin receptors FcγRIIa 
(which is activatory) and FcγRIIb (which is inhibitory) are shifted in SLE patient cells, with 
higher relative expression of FcγRIIA observed[58]. This has the effect of a loss of 
inhibitory function of FcγRIIb which contributes to hyper responsiveness of SLE immune 
cells to immune complexes [59].  Polymorphisms in the negative regulator PTPN22 are 
also used as markers in SLE, indicating that general downregulation of inhibitory 
mechanisms in SLE may be a feature of SLE [60].  More comprehensive genetic studies are 
necessary to asses if this is the case with Siglec-7 in SLE patients. 
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We wanted to look at a more specific cell populations and found that Siglec-7 is present 
at relatively high levels on monocytes when compared to other PBMC subsets [61].  The 
same trend in expression of Siglec 7 was observed in purified monocytes as was seen in 
PBMCs, but conversely an increase was seen in Siglec-7 levels in response to TLR4 
stimulation and not in response to TLR7 stimulation in patient monocytes versus controls.  
 Upregulation of Siglec-7 expression following TLR4 stimulation may be due to its 
capacity to act in an activatory role. One study previously showed that after ligation of 
Siglec-7 with the IgG2b mAb, Z-176, an increase in the production of TNFα was observed 
that was not seen in mixed or other isolated cell populations [45].  This is consistent with 
the results seen when we added Sia NPs to monocytes (discussed below). 
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4.3 Testing the Efficacy of Nanoparticles in Human Cells  
 
 While testing the expression patterns of Siglec-7 and -9, we were concurrently 
testing the efficacy of sialic acid conjugated nanoparticles (Sia NPs) on monocytes and 
PBMCs.  This was done by measuring the levels of three well-known pro-inflammatory 
cytokines, TNF-a, IL-6 and CCL5/RANTES.  TNFα is found at elevated levels in SLE patients 
and increased levels are found to be consistent with disease activity [62].  IL-6 is known to 
be over-expressed in active SLE patients [63, 64], in particular by PBMCs [65].  IL-6 over-
production has been linked to autoantibody production in patients [66].  SLE patients 
display elevated levels of RANTES production [67] and it is known to play a part in 
inflammation by recruiting T lymphocytes and monocytes to a site of infection [68].  
 In PBMCs, inhibition of cytokine production was observed when Sia NPs were 
added to LPS stimulated cells, but not when cells were stimulated with Imiquimod or CpG 
and the control NPs also showed some inhibition of RANTES production.  The most 
significant result was the non-specific proinflammatory response of the cells to the Sia 
NPs on their own.  PLGA nanoparticles are known for their biocompatibility and as such 
should not illicit such a response [69].  These variable and unexpected findings in the 
PBMC mixed population could be a result of Siglec-7 behaving in a pro-inflammatory 
fashion as shown by Varchetta et al [45] when they looked at Siglec-7 in isolated 
monocytes.  To examine this theory further, the same experiments were carried out in 
monocytes isolated from whole blood with immune complexes (ICs) from patient serum 
also being used as a stimulus (discussed below).  Again, variable results were observed. 
Some inhibition of the RANTES response to IC stimulation but overall there was no change 
or an increase in the cytokine levels, fitting with the findings of Varchetta et al.  Similar to 
the experiments in PBMCs, some basal induction of cytokines was observed in response 
to both Sia NPs and blank control NPs. 
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 Regarding the pro-inflammatory response observed with our nanoparticles, a 
possible theory is that Siglec-7 and -9 may have been bound in a cis formation and if the 
affinity for the sialic acid on the nanoparticles was not high enough they may have 
remained masked and the sialic acid bound to another receptor.  It is also possible that 
the sialic acid on the nanoparticles, while acting as a ligand for Siglec-E, may not have 
been specific for Siglec-7 or -9 and could have been interacting with another receptor, 
causing a pro-inflammatory response.  For example, Siglec-14 is a CD33-related Siglec and 
although its extracellular region is structurally similar to Siglec-7 and -9 it does not 
possess an ITIM in its cytoplasmic tail, and instead it associates with the ITAM containing 
adapter protein DAP12 [70].  The presence of an ITAM in DAP12 means that this may 
function as an activatory receptor.  Further studies using a blocking antibody against 
Siglec-14 or silencing Siglec-14 with an shRNA specific to it would be required to address 
this possibility but these studies were outside of the scope of these investigations due to 
time constraints. 
   
82 
 
 
4.3.1 Use of Immune Complexes to mimic SLE Etiology 
 
 While testing the nanoparticles in human cells we observed a lot of variability in 
the response of both PBMCs and monocytes to the TLR-9 ligand CPG.  There are three 
forms of this synthetic ligand, CpGA, CpGB and CpGC,  and some studies have shown that 
TLR-9 responds differently to each variation of this ligand [71], [72], [73], [74].   
 To resolve these inconsistencies we adapted a method [75] to extract IgG from SLE 
patient serum in the form of immune complexes (ICs) in order to stimulate our cells in a 
more SLE-like manner via TLRs 7 & 9.  It has previously been proven that ICs isolated from 
SLE patient serum cause an increase in pro-inflammatory cytokine production when 
incubated with PBMCs [76].   
 In the Siglec expression studies, when the ICs were used to stimulate both PBMCs 
and monocytes from SLE patients and controls no increase in Siglec-7 expression was 
observed in SLE patients versus controls compared to the resting cells.  This was in 
contrast to what we saw when we stimulated the cells with LPS and Imiquimod.  
However, Wiedeman et al. showed that TLR agonist-stimulated IFNα production is not 
regulated in the same manner as immune complex-stimulated IFNα production [77] and 
so this response would need to be further investigated to establish the mechanism.  
 We also saw consistent upregulation of proinflammatory cytokines, thus solving 
the issues we had when using CpG. 
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4.4 Development of a Novel Sialic Acid Assay 
 
 We still endeavored to find a sialic acid ligand that would function as a negative 
regulator in a human model.   
 The Consortium for Functional Glycomics supplied 27 biotin-labeled sialic acids.  
The structure and function of these sialic acids was examined and some were determined 
to be structurally and functionally similar or had α-linkages that were not optimal for 
Siglec-7 or -9, and so they were eliminated from the study, leaving 23 to screen for 
activity. 
 Two of the 23 sialic acids tested showed consistent inhibition of the 
proinflammatory response, Sialic Acid 2 and Sialic Acid 8, Sia2 and Sia8 respectively.  Sia8 
showed more significant inhibition of TNFα, Il-6 and RANTES.  
 Sia2 represented Sialyl Lewis C, which contains and α 2,3 linkage.  Sialyl Lewis C is 
a lesser studied sialic acid, it is a non-fucosylated variant of the more common Sialyl Lewis 
A and is associated with a transmembrane protein commonly found in pancreatic cancer 
cells [78].  We would not expect this to act as a ligand for Siglec-7 or Siglec-9 as both show 
only a very low affinity for sialic acids with the α 2,3 linkage.. Due to time constraints we 
chose not to test Sia2 any further as Sia8 displayed a greater ability to inhibit the 
proinflammatory response. 
 Sia8 was determined to be ganglioside GD3.  GD3 is an α 2,8 linked disialic acid. 
Rapoport et al demonstrated that this ganglioside displays preferential binding to CD-33 
related Siglecs [79].  In particular, the Siglec-7 and GD3 interaction has been studied in NK 
cells and has shown to reduce NK cell toxicity [29].   
 Once we had identified GD3 as having potential therapeutic properties we began 
to optimize a technique to produce PLGA nanoparticles to which we would conjugate the 
sialic acid, however this process was never finalized.  
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4.5 Conclusions and Future Work 
 
 We discovered that Siglec-7 and -9 display a different expression pattern in SLE 
patients than in healthy controls. Discovery of a ligand to activate their ability to 
negatively regulate the proinflammatory response in SLE patients requires further 
studies, however, they could be potential therapeutic targets or perhaps be used as 
markers for the disease.  
 We also identified although there is a very high level of homology between murine 
Siglec-E and human Siglec-7 & -9, the nanoparticles produced by our collaborators in QUB 
were not successful in inhibiting the induction of proinflammatory cytokines in a human 
model as they were in murine cells.  
 A method to mimic the natural mechanism of stimulation of TLRs seen in SLE 
patients was developed by isolating immune complexes from SLE patient serum. 
 We developed a novel assay that identified the sialic acid GD3 as having potential 
therapeutic capabilities by inhibiting a proinflammatory response to ICs in human cells.  
 Additional experiments to definitively identify the role of Siglec-7 as either a 
positive or negative regulator are needed. One possible method would be to overexpress 
Siglec-7 in a cell line, such as 293Ts, and study the effect on reporter genes using a 
luciferase assay.  Additionally, knockdown of Siglec-7 in monocytes using shRNA would 
provide more specific answers regarding the role Siglec-7 is playing in the upregulation of 
proinflammatory cytokines that we observed.  Assessment of DAP12 protein levels during 
stimulation by Western Blot may also give us an answer as to whether or not Siglec-14 is 
activated by the nanoparticles.    
Further work on this study is needed to efficiently conjugate the sialic acid GD3 to 
PLGA nanoparticles.  Basic nanoparticles production needs to be optimized. Varying the 
time allowed for evaporation of the DCM had an effect on the size of our particles.  The 
optimum time for evaporation needs to be calculated to obtain consistently sized 
nanoparticles.  In addition to this, the method for conjugation of GD3 to the particles also 
needs to be further assessed.  We saw no conjugation after varying GD3 concentrations 
followed by varying antibody concentrations.  The EDC concentration may also affect the 
binding efficiency.  This was only tested at one concentration and should be optimized 
further.  The efficiency of conjugation can be tested by incubating with Streptavidin APC 
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(this will bind to the nanoparticles as the exposed GD3 is biotinylated) and viewing the 
fluorescence on a flow cytometer.  We did not optimize the antibody concentration for 
this step.   
86 
 
Bibliography 
 
1. Tsokos, G.C., Systemic Lupus Erythematosus. New England Journal of Medicine, 
2011. 365(22): p. 2110-2121. 
2. Bombardier, C., et al., Derivation of the sledai. A disease activity index for lupus 
patients. Arthritis & Rheumatism, 1992. 35(6): p. 630-640. 
3. Kassi, E. and P. Moutsatsou, Estrogen Receptor Signaling and Its Relationship to 
Cytokines in Systemic Lupus Erythematosus. Journal of Biomedicine and 
Biotechnology, 2010. 2010. 
4. Smith, S., et al., Estrogen Receptor α Regulates Tripartite Motif–Containing 
Protein 21 Expression, Contributing to Dysregulated Cytokine Production in 
Systemic Lupus Erythematosus. Arthritis & Rheumatology, 2014. 66(1): p. 163-
172. 
5. Ronnblom, L. and G. Alm, Systemic lupus erythematosus and the type I interferon 
system. Arthritis Res Ther, 2003. 5(2): p. 68 - 75. 
6. Lövgren, T., et al., Induction of interferon-α production in plasmacytoid dendritic 
cells by immune complexes containing nucleic acid released by necrotic or late 
apoptotic cells and lupus IgG. Arthritis & Rheumatism, 2004. 50(6): p. 1861-1872. 
7. Leadbetter, E., et al., Chromatin-IgG complexes activate B cells by dual 
engagement of IgM and Toll-like receptors. Nature, 2002. 416: p. 603 - 607. 
8. Smith, S., et al., Estrogen receptor alpha regulates tripartite motif-containing 
protein 21 expression, contributing to dysregulated cytokine production in systemic 
lupus erythematosus. Arthritis Rheumatol, 2014. 66(1): p. 163-72. 
9. Kono, D.H., et al., Endosomal TLR signaling is required for anti-nucleic acid and 
rheumatoid factor autoantibodies in lupus. Proceedings of the National Academy 
of Sciences, 2009. 106(29): p. 12061-12066. 
10. García-Ortiz, H., et al., Association of TLR7 copy number variation with 
susceptibility to childhood-onset systemic lupus erythematosus in Mexican 
population. Annals of the Rheumatic Diseases, 2010. 69(10): p. 1861-1865. 
11. Papadimitraki, E.D., et al., Expansion of toll-like receptor 9–expressing B cells in 
active systemic lupus erythematosus: Implications for the induction and 
maintenance of the autoimmune process. Arthritis & Rheumatism, 2006. 54(11): p. 
3601-3611. 
12. Coca, A.a. and I.b. Sanz, Updates on B-cell immunotherapies for systemic lupus 
erythematosus and Sjogren's syndrome. Current Opinion in Rheumatology, 2012. 
24(5): p. 451-456. 
13. Higgs, R., et al., The E3 Ubiquitin Ligase Ro52 Negatively Regulates IFN-β 
Production Post-Pathogen Recognition by Polyubiquitin-Mediated Degradation 
of IRF3. The Journal of Immunology, 2008. 181(3): p. 1780-1786. 
14. Stacey, K.B., E. Breen, and C.A. Jefferies, Tyrosine phosphorylation of the E3 
ubiquitin ligase TRIM21 positively regulates interaction with IRF3 and hence 
TRIM21 activity. PLoS One, 2012. 7(3): p. e34041. 
15. Gabhann, J.N., et al., Absence of SHIP-1 results in constitutive phosphorylation of 
tank-binding kinase 1 and enhanced TLR3-dependent IFN-beta production. J 
Immunol, 2010. 184(5): p. 2314-20. 
16. Ong, C.J., et al., Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-
kinase pathway in hematopoietic cells. Blood, 2007. 110(6): p. 1942-9. 
17. Stenton, G.R., et al., Characterization of AQX-1125, a small-molecule SHIP1 
activator. British Journal of Pharmacology, 2013. 168(6): p. 1519-1529. 
87 
 
18. Riva, F., et al., TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor 
Family Member with Regulatory Functions in Inflammation and Immunity. Front 
Immunol, 2012. 3: p. 322. 
19. Lech, M., et al., Tir8/Sigirr prevents murine lupus by suppressing the 
immunostimulatory effects of lupus autoantigens. J Exp Med, 2008. 205(8): p. 
1879-88. 
20. Savarese, E., et al., Requirement of Toll-like receptor 7 for pristane-induced 
production of autoantibodies and development of murine lupus nephritis. Arthritis 
Rheum, 2008. 58(4): p. 1107-15. 
21. Qingxian, L., L. Qiutang, and L. Qingjun, Regulation of phagocytosis by TAM 
receptors and their ligands. Front Biol (Beijing), 2010. 5(3): p. 227-237. 
22. Li, Q., et al., Systemic autoimmunity in TAM triple knockout mice causes 
inflammatory brain damage and cell death. PLoS One, 2013. 8(6): p. e64812. 
23. Liberal, R., et al., The impaired immune regulation of autoimmune hepatitis is 
linked to a defective galectin-9/tim-3 pathway. Hepatology, 2012. 56(2): p. 677-
686. 
24. Koguchi, K., et al., Dysregulated T cell expression of TIM3 in multiple sclerosis. 
The Journal of Experimental Medicine, 2006. 203(6): p. 1413-1418. 
25. Wang, C., et al., Therapeutic potential of SIGIRR in systemic lupus erythematosus. 
Rheumatology International, 2013. 33(8): p. 1917-1921. 
26. Heikema, A.P., et al., Siglec-7 specifically recognizes Campylobacter jejuni strains 
associated with oculomotor weakness in Guillain–Barré syndrome and Miller 
Fisher syndrome. Clinical Microbiology and Infection, 2013. 19(2): p. E106-E112. 
27. Ruslan, M., P.-H. Paula, and A.J. Charles, A human homologue of the Drosophila 
Toll protein signals activation of adaptive immunity. Nature, 1997. 388(6640): p. 
394-397. 
28. Ohta, M., et al., Immunomodulation of monocyte-derived dendritic cells through 
ligation of tumor-produced mucins to Siglec-9. Biochemical and Biophysical 
Research Communications, 2010. 402(4): p. 663-669. 
29. Nicoll, G., et al., Ganglioside GD3 expression on target cells can modulate NK cell 
cytotoxicity via siglec-7-dependent and -independent mechanisms. European 
Journal of Immunology, 2003. 33(6): p. 1642-1648. 
30. Orr, S.J., et al., SOCS3 Targets Siglec 7 for Proteasomal Degradation and Blocks 
Siglec 7-mediated Responses. Journal of Biological Chemistry, 2007. 282(6): p. 
3418-3422. 
31. Cao, H. and P.R. Crocker, Evolution of CD33-related siglecs: regulating host 
immune functions and escaping pathogen exploitation? Immunology, 2011. 132(1): 
p. 18-26. 
32. Boyd, C.R., et al., Siglec-E Is Up-Regulated and Phosphorylated Following 
Lipopolysaccharide Stimulation in Order to Limit TLR-Driven Cytokine 
Production. The Journal of Immunology, 2009. 183(12): p. 7703-7709. 
33. Varki, A. and R. Schauer, Sialic Acids, in Essentials of Glycobiology, A. Varki, et 
al., Editors. 2009: Cold Spring Harbor (NY). 
34. Lanoue, A., et al., Interaction of CD22 with alpha2,6-linked sialoglycoconjugates: 
innate recognition of self to dampen B cell autoreactivity? Eur J Immunol, 2002. 
32(2): p. 348-55. 
35. Avgoustakis, K., Pegylated poly(lactide) and poly(lactide-co-glycolide) 
nanoparticles: preparation, properties and possible applications in drug delivery. 
Curr Drug Deliv, 2004. 1(4): p. 321-33. 
88 
 
36. Snima, K.S., et al., Silymarin encapsulated poly(D,L-lactic-co-glycolic acid) 
nanoparticles: a prospective candidate for prostate cancer therapy. J Biomed 
Nanotechnol, 2014. 10(4): p. 559-70. 
37. Diez, S., G. Navarro, and I.C.T. de, In vivo targeted gene delivery by cationic 
nanoparticles for treatment of hepatocellular carcinoma. J Gene Med, 2009. 11(1): 
p. 38-45. 
38. Chaudhary, A., et al., Chemoprevention of colon cancer in a rat carcinogenesis 
model using a novel nanotechnology-based combined treatment system. Cancer 
Prev Res (Phila), 2011. 4(10): p. 1655-64. 
39. Laroui, H., et al., Drug-loaded nanoparticles targeted to the colon with 
polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology, 2010. 
138(3): p. 843-53 e1-2. 
40. Xiao, B., et al., Nanoparticles with surface antibody against CD98 and carrying 
CD98 small interfering RNA reduce colitis in mice. Gastroenterology, 2014. 
146(5): p. 1289-300 e1-19. 
41. Simion, V., et al., Development of curcumin-loaded poly(hydroxybutyrate-co-
hydroxyvalerate) nanoparticles as anti-inflammatory carriers to human-activated 
endothelial cells. Journal of Nanoparticle Research, 2013. 15(12): p. 1-15. 
42. Bondioli, L., et al., PLGA nanoparticles surface decorated with the sialic acid, N-
acetylneuraminic acid. Biomaterials, 2010. 31(12): p. 3395-403. 
43. Ando, M., et al., Siglec-9 enhances IL-10 production in macrophages via tyrosine-
based motifs. Biochemical and Biophysical Research Communications, 2008. 
369(3): p. 878-883. 
44. McCarthy, E.M., et al., The association of cytokines with disease activity and 
damage scores in systemic lupus erythematosus patients. Rheumatology (Oxford), 
2014. 
45. Varchetta, S., et al., Engagement of Siglec-7 receptor induces a pro-inflammatory 
response selectively in monocytes. PLoS One, 2012. 7(9): p. e45821. 
46. Yu, Z., et al., mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding 
immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing 
protein tyrosine phosphatases SHP-1 and SHP-2. Biochem J, 2001. 353(Pt 3): p. 
483-92. 
47. Zhang, J.Q., et al., The murine inhibitory receptor mSiglec-E is expressed broadly 
on cells of the innate immune system whereas mSiglec-F is restricted to 
eosinophils. Eur J Immunol, 2004. 34(4): p. 1175-84. 
48. Kim, J.H., et al., Self-assembled glycol chitosan nanoparticles for the sustained and 
prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. 
Biomaterials, 2008. 29(12): p. 1920-30. 
49. Liao, W.Y., et al., Comprehensive characterizations of nanoparticle biodistribution 
following systemic injection in mice. Nanoscale, 2013. 5(22): p. 11079-86. 
50. Huang, X., et al., Effect of injection routes on the biodistribution, clearance, and 
tumor uptake of carbon dots. ACS Nano, 2013. 7(7): p. 5684-93. 
51. Jung, C., et al., Intraperitoneal injection improves the uptake of nanoparticle-
labeled high-density lipoprotein to atherosclerotic plaques compared with 
intravenous injection: a multimodal imaging study in ApoE knockout mice. Circ 
Cardiovasc Imaging, 2014. 7(2): p. 303-11. 
52. Harivardhan Reddy, L., et al., Influence of administration route on tumor uptake 
and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's 
lymphoma tumor bearing mice. J Control Release, 2005. 105(3): p. 185-98. 
89 
 
53. Attrill, H., et al., The structure of siglec-7 in complex with sialosides: leads for 
rational structure-based inhibitor design. Biochem J, 2006. 397(2): p. 271-8. 
54. Angata, T. and A. Varki, Cloning, characterization, and phylogenetic analysis of 
siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-
evolution with sialic acid synthesis pathways. J Biol Chem, 2000. 275(29): p. 
22127-35. 
55. Angata, T. and A. Varki, Siglec-7: a sialic acid-binding lectin of the 
immunoglobulin superfamily. Glycobiology, 2000. 10(4): p. 431-8. 
56. Ikehara, Y., S.K. Ikehara, and J.C. Paulson, Negative regulation of T cell receptor 
signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem, 2004. 279(41): p. 
43117-25. 
57. Lech, M., et al., Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus 
nephritis. The Journal of Pathology, 2010. 220(5): p. 596-607. 
58. Reefman, E., et al., Fc[ggr] receptors in the initiation and progression of systemic 
lupus erythematosus. Immunol Cell Biol, 2003. 81(5): p. 382-389. 
59. Dijstelbloem, H.M., et al., Fcgamma receptor polymorphisms in systemic lupus 
erythematosus: association with disease and in vivo clearance of immune 
complexes. Arthritis Rheum, 2000. 43(12): p. 2793-800. 
60. Orozco, G., et al., Association of a functional single-nucleotide polymorphism of 
PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and 
systemic lupus erythematosus. Arthritis Rheum, 2005. 52(1): p. 219-24. 
61. Nicoll, G., et al., Identification and Characterization of a Novel Siglec, Siglec-7, 
Expressed by Human Natural Killer Cells and Monocytes. Journal of Biological 
Chemistry, 1999. 274(48): p. 34089-34095. 
62. Aringer, M., et al., Increased bioactive TNF in human systemic lupus 
erythematosus: associations with cell death. Lupus, 2002. 11(2): p. 102-8. 
63. Ohl, K. and K. Tenbrock, Inflammatory cytokines in systemic lupus erythematosus. 
J Biomed Biotechnol, 2011. 2011: p. 432595. 
64. Linker-Israeli, M., et al., Elevated levels of endogenous IL-6 in systemic lupus 
erythematosus. A putative role in pathogenesis. J Immunol, 1991. 147(1): p. 117-
23. 
65. Dong, G., et al., IL-17 induces autoantibody overproduction and peripheral blood 
mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J 
(Engl), 2003. 116(4): p. 543-8. 
66. Tackey, E., P.E. Lipsky, and G.G. Illei, Rationale for interleukin-6 blockade in 
systemic lupus erythematosus. Lupus, 2004. 13(5): p. 339-43. 
67. Eriksson, C., et al., Abnormal expression of chemokine receptors on T-cells from 
patients with systemic lupus erythematosus. Lupus, 2003. 12(10): p. 766-74. 
68. Ye, D.Q., et al., Polymorphisms in the promoter region of RANTES in Han Chinese 
and their relationship with systemic lupus erythematosus. Arch Dermatol Res, 
2005. 297(3): p. 108-13. 
69. Cruz, L.J., et al., Targeted PLGA nano- but not microparticles specifically deliver 
antigen to human dendritic cells via DC-SIGN in vitro. J Control Release, 2010. 
144(2): p. 118-26. 
70. Angata, T., et al., Discovery of Siglec-14, a novel sialic acid receptor undergoing 
concerted evolution with Siglec-5 in primates. FASEB J, 2006. 20(12): p. 1964-73. 
71. Sivori, S., et al., Comparison of different CpG oligodeoxynucleotide classes for 
their capability to stimulate human NK cells. European Journal of Immunology, 
2006. 36(4): p. 961-967. 
90 
 
72. Hartmann, G., et al., Rational design of new CpG oligonucleotides that combine B 
cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J 
Immunol, 2003. 33(6): p. 1633-41. 
73. Kerkmann, M., et al., Activation with CpG-A and CpG-B Oligonucleotides Reveals 
Two Distinct Regulatory Pathways of Type I IFN Synthesis in Human Plasmacytoid 
Dendritic Cells. The Journal of Immunology, 2003. 170(9): p. 4465-4474. 
74. Krug, A., et al., CpG-A oligonucleotides induce a monocyte-derived dendritic cell-
like phenotype that preferentially activates CD8 T cells. J Immunol, 2003. 170(7): 
p. 3468-77. 
75. Owens, G.P., et al., Extraction and purification of active IgG from SSPE and MS 
brain. J Virol Methods, 1997. 68(2): p. 119-25. 
76. Means, T.K., et al., Human lupus autoantibody-DNA complexes activate DCs 
through cooperation of CD32 and TLR9. J Clin Invest, 2005. 115(2): p. 407-17. 
77. Wiedeman, A.E., et al., Contrasting Mechanisms of Interferon-α Inhibition by 
Intravenous Immunoglobulin After Induction by Immune Complexes Versus Toll-
like Receptor Agonists. Arthritis & Rheumatism, 2013. 65(10): p. 2713-2723. 
78. Aubert, M., et al., Restoration of alpha(1,2) fucosyltransferase activity decreases 
adhesive and metastatic properties of human pancreatic cancer cells. Cancer Res, 
2000. 60(5): p. 1449-56. 
79. Rapoport, E., et al., Ganglioside binding pattern of CD33-related siglecs. Bioorg 
Med Chem Lett, 2003. 13(4): p. 675-8. 
 
